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A B S T R A C T
Background
Schizophrenia is a highly prevalent and chronic disorder that comprises a wide range of symptomatology. Asenapine is a recently
developed atypical antipsychotic that is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia.
Objectives
To determine the clinical effects of asenapine for adults with schizophrenia or other schizophrenia-like disorders by comparing it with
placebo.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (July 04, 2014) which is based on regular searches of MEDLINE,
EMBASE, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries of clinical trials. There are no language, date, document
type, or publication status limitation for inclusion of records into the register. We inspected references of all included studies for further
relevant studies.
Selection criteria
Our review includes randomised controlled trials (RCTs) comparing asenapinewith placebo in adults (however defined)with schizophre-
nia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of
diagnosis.
Data collection and analysis
We inspected citations from the searches and identified relevant abstracts, and extracted data from all included studies. For binary data
we calculated risk ratio (RR) with 95% confidence intervals (CI), and for continuous data we calculated mean differences (MD). We
used the GRADE approach to produce a ’Summary of findings’ table which included our outcomes of interest, where possible. We
used a fixed-effect model for our analyses.
Main results
We obtained and scrutinised 41 potentially relevant records, and from these we could include only six trials (n = 1835). Five of the six
trials had high risk of attrition bias and all trials were sponsored by pharmaceutical companies. Results showed a clinically important
change in global state (1 RCT, n = 336, RR 0.81, 95% CI 0.68 to 0.97, low-quality evidence) and mental state (1 RCT, n = 336, RR
0.72, 95% CI 0.59 to 0.86, very low-quality evidence) at short-term amongst people receiving asenapine. People receiving asenapine
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demonstrated significant reductions in negative symptoms (1 RCT, n = 336, MD -1.10, 95% CI -2.29 to 0.09, very low-quality
evidence) at short-term. Individuals receiving asenapine demonstrated significantly fewer incidents of serious adverse effects (1 RCT, n =
386, RR 0.29, 95% CI 0.14 to 0.63, very low-quality evidence) at medium-term. There was no clear difference in people discontinuing
the study for any reason between asenapine and placebo at short-term (5 RCTs, n = 1046, RR 0.91, 95% CI 0.80 to 1.04, very low-
quality evidence). No trial reported data for extrapyramidal symptoms or costs.
Authors’ conclusions
There is some, albeit preliminary, evidence that asenapine provides an improvement in positive, negative, and depressive symptoms,
whilst minimising the risk of adverse effects. However due to the low-quality and limited quantity of evidence, it remains difficult to
recommend the use of asenapine for people with schizophrenia. We identify a need for large-scale, longer-term, better-designed and
conducted randomised controlled trials investigating the clinical effects and safety of asenapine.
P L A I N L A N G U A G E S U M M A R Y
Asenapine versus placebo for schizophrenia
Review question
Asenapine is a newer antipsychotic drug developed in the early-to-mid 1990s. The review looks at the effects of asenapine in the
treatment of schizophrenia compared with placebo.
Background
People with schizophrenia often have ’positive symptoms’, such as hearing voices, seeing things (hallucinations) and strange beliefs
(delusions). People also have ’negative symptoms’, including loss of emotions, apathy, social withdrawal, lack of pleasure and difficulty
speaking and communicating. Disorder of thoughts, anxiety and depression are common. The main treatment for these symptoms
of schizophrenia is antipsychotic drugs, which are divided into older drugs (typical or first generation) and newer drugs (atypical or
second generation). These drugs often have severe side effects, such as weight gain, muscle stiffness, involuntary shaking and tiredness.
Asenapine is a newer antipsychotic drug developed in the 1990s. At present there are no systematic reviews assessing the effects of this
drug.
Study characteristics
The review includes six trials with 1835 people. The trials randomised people with schizophrenia to receive either asenapine or placebo.
Five of these trials had high rates of people leaving early and were sponsored by pharmaceutical companies.
Key results
There is some evidence that asenapine, when compared to placebo, improves the positive, negative and depressive symptoms of
schizophrenia while having less risk of debilitating side effects.
Quality of the evidence
However, due to the low quantity and limited quality of evidence currently available, it remains difficult to recommend the use of
asenapine for schizophrenia. There is a need for large-scale, longer-term followup, andbias-free randomised controlled trials investigating
the effects and safety of asenapine.
Ben Gray, Senior Peer Researcher, McPin Foundation. http://mcpin.org/
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
ASENAPINE versus PLACEBO for schizophrenia
Patient or population: adults with schizophrenia
Settings: inpat ient and outpat ient
Intervention: ASENAPINE versus PLACEBO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control ASENAPINE versus
PLACEBO
Global state: No clini-
cally important change
CGI-I
Follow-up: up to 12
weeks
Study population RR 0.81
(0.68 to 0.97)
336
(1 study)
⊕⊕©©
low1,2,3
664 per 1000 538 per 1000
(451 to 644)
M oderate
664 per 1000 538 per 1000
(452 to 644)
M ental state: No clini-
cally important change
PANSS
Follow-up: up to 12
weeks
Study population RR 0.72
(0.59 to 0.86)
336
(1 study)
⊕©©©
very low1,2,3,4
672 per 1000 484 per 1000
(397 to 578)
M oderate
672 per 1000 484 per 1000
(396 to 578)
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M ental state: Average
change score in nega-
tive symptoms
PANSS Marder nega-
t ive factor score
Follow-up: up to 12
weeks
The mean mental state: average change score
in negat ive symptoms in the intervent ion groups
was
1.1 lower
(2.29 lower to 0.09 higher)
336
(1 study)
⊕©©©
very low1,2,3,4
Adverse effects: Inci-
dence of serious ad-
verse effects
Follow-up: 13-26 weeks
Study population RR 0.29
(0.14 to 0.63)
386
(1 study)
⊕©©©
very low2,3,5,6,7
141 per 1000 41 per 1000
(20 to 89)
M oderate
141 per 1000 41 per 1000
(20 to 89)
Adverse effects: Clini-
cally significant
extrapyramidal symp-
toms
AIMS
Follow-up: 13-26 weeks
No trial reported this outcome.
Leaving the study early
- any reason
Follow-up: up to 12
weeks
Study population RR 0.91
(0.80 to 1.04)
1046
(5 studies)
⊕©©©
very low10,11,12
488 per 1000 444 per 1000
(390 to 507)
M oderate
484 per 1000 440 per 1000
(387 to 503)
Economic costs No trial reported this outcome.
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: ’Very serious’ - Random sequence generat ion, allocat ion concealment and blinding (part icipants/ personnel and
outcome assessment) are poorly described.
2 Risk of bias: ’Very serious’ - Attrit ion bias (method of analysis for dealing with incomplete data was last observat ion carried
forward) and other bias (associat ion with and funded by pharmaceut ical companies) were sources of high risk.
3 Inconsistency: ’No’ - Only one study.
4 Indirectness: ’Serious’ - Marder factor scores determ ined using factor analysis of PANSS items.
5 Risk of bias: ’Very serious’ - Random sequence generat ion and allocat ion concealment are poorly described.
6 Risk of bias: ’Very serious’ - Blinding of outcome assessment (possibility of biased judgement) and report ing bias (insuf f icient
data reported for certain outcomes) were sources of high risk.
7 Imprecision: ’Serious’ - Low event rate.
8 Indirectness: ’Serious’ - AIMS specif ically assesses tardive dyskinesia.
9 Imprecision: ’Serious’ - Wide conf idence interval.
10 Risk of bias: ’Very serious’ - Blinding of part icipants/ personnel (four of f ive studies), attrit ion bias (four of f ive studies),
select ive report ing (four of f ive studies) and other bias (all f ive studies) were sources of high risk.
11 Inconsistency: ’Serious’ - This outcome had moderate levels of heterogeneity due to one study (I2 = 43%).
12 Imprecision: ’No’ - Large event rate and sample with a narrow conf idence interval.
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B A C K G R O U N D
Description of the condition
Schizophrenia affects approximately 0.3% to 0.7% of people dur-
ing their lifetime, with an estimated 24 million individuals expe-
riencing the disorder worldwide (McGrath 2008; WHO 2014).
With similar prevalence and incidence rates globally, it iswidely ac-
cepted that schizophrenia is associated with significant global bur-
den (Ayuso-Mateos 2006). The prevalence rates of schizophrenia
are similar for men and women (Saha 2005). With a considerably
variable age of onset, schizophrenia can present for the first time
from adolescence, through middle age (late-onset schizophrenia),
and up to old age (very late-onset schizophrenia-like psychosis)
(Kohler 2007). It has been established that an interaction of mul-
tiple genetic and environmental factors are involved in the aetiol-
ogy of schizophrenia (vanOs 2008). Such heterogeneous aetiology
may contribute to the diverse illness course and symptomatology
seen in the disease (Andreasen 1999; Walker 2004).
Schizophrenia is typically considered in relation to the dichotomy
of positive symptoms such as delusions and hallucinations, which
are characterised by their atypical presence; and negative symp-
toms, such as poverty of speech, flattened affect, lack of plea-
sure (anhedonia), and lack of motivation (avolition) (Crow 1980).
Moreover, patients with schizophrenia can express a disorganised
state primarilymarkedby disorganised thought and speech, known
as formal thought disorder (Liddle 1987). Mood symptoms such
as depression and anxiety are also very common in schizophre-
nia yet are heterogeneous in nature and so require thorough in-
vestigation (Siris 2000). Furthermore, there is increasing evidence
that people with schizophrenia exhibit deficits in several domains
of cognitive functioning including memory, language, executive
functioning and attention (Fioravanti 2005).
Description of the intervention
Antipsychotic drugs are used as first-line medication for
schizophrenia. Typical (or first-generation) antipsychotics, such
as chlorpromazine and haloperidol, have been available since the
1950s, whilst atypical (or second-generation) antipsychotics, such
as clozapine and olanzapine, have been introduced from the late
1980s (Lehmann 1997). Atypical antipsychotics have beenmarked
as producing greater reductions in negative and mood symptoms,
whilst minimising adverse effects usually observed during typical
antipsychotic treatment, such as extrapyramidal symptoms and
hyperprolactinaemia (Davis 2003; Worrel 2000). However, atyp-
ical antipsychotics are not without their own adverse effects in-
cluding sedation, sexual dysfunction, weight gain, diabetes, and
cardiovascular problems (Muench 2010).
Asenapine is a novel second-generation antipsychotic originally
developed by Organon in the early-to-mid 1990s, which was ap-
proved by the US Food and Drug Administration (FDA) in 2009
for the acute treatment of adults with schizophrenia and bipolar
I disorder (Citrome 2009). However, in the European Union and
the UK it is currently approved for the acute treatment of bipolar
I disorder only and not for schizophrenia (EMA 2014).
Initial investigation of the properties and clinical effects of ase-
napine has begun (Stoner 2012), although the use of placebo-con-
trolled clinical trials can be difficult to justify, particularly when
evidence-based pharmacological treatments for schizophrenia al-
ready exist (Emsley 2013). However, aside from investigating the
comparative effects of novel antipsychotic drugs with others that
are currently available, it is important to consider the absolute
effects of medication purported to be antipsychotic (Storosum
1998).
How the intervention might work
Asenapine is predominantly administered sublingually (5 mg to
10 mg twice daily) due to previous reports of low bioavailability
when administered orally, and typically reaches peak plasma levels
within 30 to 90 minutes following absorption via the oral mucosa
(FDA 2013).
Asenapine is a novel second-generation antipsychotic drug (see
Figure 1 for its chemical structure). It has a somewhat unique phar-
macological profile compared to alternative atypical antipsychotic
medication and has a greater affinity for a range of serotoner-
gic, dopaminergic, noradrenergic, and histamine receptors, acting
through the antagonism of most of these receptor subtypes, whilst
expressing low affinity to muscarinic receptors (Shahid 2009). It
has been proposed that antagonism of dopamine and noradrener-
gic receptors contributes substantially to the alleviation of positive
symptoms in schizophrenia (Abi-Dargham 2004; Svensson 2003).
Additionally, the antagonism of serotonergic receptors may im-
prove negative, cognitive and mood symptoms of schizophrenia
(Hedlund 2004; Meltzer 1999).
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Figure 1. Chemical structure of asenapine
With its low affinity to muscarinic receptors, asenapine may min-
imise the risk of anticholinergic adverse effects reported following
the use of some antipsychotic drugs (Lieberman 2004). However,
histamine antagonism is known to produce sedation (Nicholson
1983), which is one of several adverse effects that have been iden-
tified following the use of asenapine, in addition to anxiety, ex-
trapyramidal symptoms, nausea/vomiting, oral hypoesthesia, and
weight gain (Sycrest 2014).
Why it is important to do this review
It is well known that both typical and atypical antipsychotics can
be costly and have an assorted adverse event profile, yet they still do
not fully meet the treatment needs of people with schizophrenia
(Campbell 1999). As asenapine is one of the more recently devel-
oped second-generation antipsychotic drugs with multi-targeted
pharmacological action, it has been suggested that it may have the
potential to produce clinical improvements in negative and cog-
nitive symptoms, as well as positive symptoms of schizophrenia,
whilst minimising the incidence of adverse effects (Bishara 2009).
At present there are no systematic reviews assessing the clinical
effects of asenapine, although there are two currently underway
comparing asenapine to typical antipsychotics and other atypical
antipsychotics (Kumar 2012; Preda 2010). Therefore, the pur-
pose of this systematic review is to summarise evidence from ran-
domised controlled trials comparing the clinical effects and safety
of asenapine to placebo amongst adults with schizophrenia and
other schizophrenia-like disorders.
O B J E C T I V E S
To determine the clinical effects of asenapine for adults with
schizophrenia or other schizophrenia-like disorders by comparing
it with placebo.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials (RCTs). If a trial had
been described as ’double-blind’ and implied that randomisation
occurred but did not state it overtly, we intended to include it in
a sensitivity analysis (see Sensitivity analysis). If inclusion of such
trials did not result in a substantive difference, they were to remain
in the analyses. If their inclusion resulted in important clinically
significant (but not necessarily clear differences), we would not
add the data from these lower quality studies to the results of
the better trials, but present such data within a subcategory. We
excluded quasi-randomised studies, such as those that allocate to
treatment groups by alternate days of the week. Where people are
given additional treatments within asenapine, we only included
the data if the adjunct treatment was evenly distributed between
groups and only asenapine was randomised.
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Types of participants
Adults with schizophrenia or related disorders, however defined,
including schizophreniform disorder, schizoaffective disorder and
delusional disorder, again, by any means of diagnosis. Where trials
included participants with a range of disorders we only included
trials where over 50% of the participants have schizophrenia.
We are interested in making sure that information is as relevant
to the current care of people with schizophrenia as possible, so
where information was available we highlighted clearly the current
clinical state of participants (acute, early post-acute, partial remis-
sion, remission) as well as the stage (prodromal, first episode, early
illness, persistent) and whether the studies primarily focused on
people with particular problems (for example, negative symptoms,
treatment-resistant illnesses).
Types of interventions
1. Asenapine
Any dose, any method of administration.
2. Placebo
Any method of administration.
Types of outcome measures
Where possible, we divided outcomes into short-term (up to 12
weeks), medium-term (13 weeks to 26 weeks) and long-term (over
26 weeks).
Primary outcomes
1. Global state
1.1 Clincally important change in global state as defined by each
study
2. Mental state
2.1 Clinically important change in mental state as defined by each
study
3. Adverse effects
3.1 Incidence of serious adverse effects
Secondary outcomes
1. Global state
1.1 Average endpoint in global state
1.2 Average change in global state (baseline to endpoint)
1.3 Relapse as defined by each study
1.4 Use of any concomitant medication
1.4.1 Use of specific concomitant medication
1.5 Adherence to trial medication
2. Mental state
2.1 General symptoms
2.1.1 Average endpoint in general mental state score
2.1.2 Average change in general mental state score (baseline to
endpoint)
2.2 Average endpoint in specific symptoms
2.2.1 Positive symptoms (delusions, hallucinations)
2.2.2 Negative symptoms (avolition, poor self care, blunted affect)
2.2.3 Mood (anxiety, depression, mania)
2.2.4 Other psychotic symptoms (e.g. disorganised thought)
2.3. Average change in specific symptoms (positive, negative,
mood, other symptoms, baseline to endpoint)
3. Cognitive functioning
3.1 General cognitive functioning as defined by each study
3.1.1Clinically important change in general cognitive functioning
as defined by each study
3.1.2 Average endpoint in general cognitive functioning
3.1.3 Average change in general cognitive functioning (baseline to
endpoint)
3.2 Specific cognitive functioning as defined by each study
3.2.1Clinically important change in specific cognitive functioning
as defined by each study
3.2.2 Average endpoint in specific cognitive functioning
3.2.3 Average change in specific cognitive functioning (baseline to
endpoint)
4. Behaviour
4.1 General behaviour as defined by each study
4.1.1 Clinically important change in general behaviour as defined
by each study
4.1.2 Average endpoint in general behaviour
4.1.3 Average change in general behaviour (baseline to endpoint)
4.2 Specific behaviour as defined by each study
4.2.1 Clinically important change in specific behaviour as defined
by each study
4.2.2 Average endpoint in specific behaviour
4.2.3 Average change in specific behaviour (baseline to endpoint)
5. Functioning
5.1 General functioning as defined by each study
5.1.1 Clinically important change in general functioning as de-
fined by each study
5.1.2 Average endpoint in general functioning
5.1.3Average change in general functioning (baseline to endpoint)
8Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.2 Specific functioning as defined by each study
5.2.1 Clinically important change in specific functioning as de-
fined by each study
5.2.2 Average endpoint in specific functioning
5.2.3Average change in specific functioning (baseline to endpoint)
6. Adverse effects
6.1 Incidence of any adverse effects
6.1.1 Incidence of adverse effects by severity as defined by each
study (excluding serious adverse effects)
6.2 Incidence of other specific adverse effects as defined by each
study
6.3 Extrapyramidal symptoms
6.3.1 Incidence of extrapyramidal symptoms
6.3.2 Clinically important extrapyramidal symptoms as defined
by each study
6.3.3 Average score/change in extrapyramidal symptoms
6.4 Deaths, by suicide or natural causes
7. Leaving the study early - for any reason
8. Service utilisation outcomes
8.1 Hospital admissions
8.2 Days in hospital
9. Quality of life
9.1 Clinically important change in quality of life
9.2 Average endpoint in quality of life
9.3 Average change in quality of life (baseline to endpoint)
10. Economic outcomes
’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2011), anduse GRADEPROprofiler to import data fromRevMan
5 (Review Manager) to create a ’Summary of findings’ table. This
table provides outcome-specific information concerning the over-
all quality of evidence from each included study in the compar-
ison, the magnitude of effect of the interventions examined, and
the sum of available data on all outcomes we rate as important
to patient-care and decision making. We selected the following
main outcomes for inclusion in Summary of findings for the main
comparison:
• Global state - clinically important change in global state as
defined by each study
• Mental state - clinically important change in mental state as
defined by each study
• Mental state - average change in negative symptoms
• Adverse effects - incidence of serious adverse effects
• Adverse effects - clinically significant extrapyramidal
symptoms
• Leaving the study early - for any reason
• Economic outcome
Search methods for identification of studies
Electronic searches
The Trials Search Coordinator (TSC) searched the Cochrane
Schizophrenia Group’s Trials Register (04 July, 2014) using the
following search strategies:
((Saphris or “ORG 5222” or asenapine) and placebo) in Title
or Abstract Fields of REFERENCE Records or (asenapine and
placebo) in Intervention Fields of STUDY Records.
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major resources (including MEDLINE,
EMBASE, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and
registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group
Module). There are no language, date, document type, or publi-
cation status limitation for inclusion of records into the register.
Searching other resources
1. Reference searching
We inspected references of all included studies for further relevant
studies.
2. Personal contact
If necessary we contacted the first author, relevant pharmaceutical
companies, and drug approval agencies of trials for additional in-
formation. We noted the outcome of this contact in the included
or awaiting assessment studies tables.
Data collection and analysis
Selection of studies
AH, AB, MS, MB, SD and IJ independently inspected citations
from the searches and identified relevant abstracts. A random 20%
sample was independently re-inspected by AH, AB, MS, MB and
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SD to ensure reliability. If disputes arose, we acquired the full re-
port for more detailed scrutiny. AH, AB, MS, MB and SD ob-
tained and inspected full reports of the abstracts meeting the re-
view criteria. Again, AH, AB, MS,MB and SD re-inspected a ran-
dom 20% of reports in order to ensure reliable selection. If it was
not possible to resolve disagreement by discussion, we attempted
to contact the authors of the study for clarification.
Data extraction and management
1. Extraction
Review authors AH and AB extracted data from all included stud-
ies. In addition, to ensure reliability, MS independently extracted
data from a random sample of these studies, comprising 10% of
the total. Again, any disagreement was discussed, decisions doc-
umented and, if necessary, authors of studies contacted for clar-
ification. We extracted data presented only in graphs and figures
whenever possible, but we only included these data if two review-
ers independently obtained the same result. We attempted to con-
tact authors through an open-ended request in order to obtain
missing information or for clarification whenever necessary. For
multi-centred studies, where possible, we extracted data relevant
to each component centre separately.
2. Management
2.1 Forms
We extracted data onto standard, pre-designed simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
and
• the measuring instrument had not been written or modified
by one of the trialists for that particular trial.
Ideally the measuring instrument should be either a self-report,
or a report completed by an independent rater or relative (not
the therapist). We realise that this is not often reported clearly; in
Description of studies we noted if this is the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis, however, calculation of change needs two assessments
(baseline and endpoint) which can be difficult to achieve in unsta-
ble and difficult-to-measure conditions such as schizophrenia. We
decided primarily to use endpoint data, and only use change data if
the former were not available. We combined endpoint and change
data in the analysis as we prefered to use mean differences (MD)
rather than standardised mean differences throughout (Higgins
2011a).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards
to all data before inclusion.
For large studies and change data
We entered all relevant useable endpoint data from studies of at
least 200 participants in the analysis, because skewed data pose
less of a problem in large studies. We also entered all change data,
as when continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult
to tell whether data are skewed or not.
For endpoint data from smaller studies (< 200)
• When a scale starts from the nite number zero, we
subtracted the lowest possible value from the mean, and divided
this by the standard deviation. If this value is lower than one, it
strongly suggests a skew and we excluded the study data. If this
ratio is higher than one but below two, there is suggestion of
skew. We entered the study data and tested whether its inclusion
or exclusion would change the results substantially. Finally, if the
ratio is larger than two we included the study data, because skew
is less likely (Altman 1996; Higgins 2011a).
• If a scale starts from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS (Kay 1986), which can
have values from 30 to 210), we modified the calculation
described above to take the scale starting point into account. In
these cases skew is present if 2 SD > (S - S min), where S is the
mean score and ’S min’ is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we converted, where rel-
evant, variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
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2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962),
or the Positive andNegative Syndrome Scale (PANSS) (Kay 1986),
this could be considered as a clinically significant response (Leucht
2005). If data based on these thresholds were not available, we
used the primary cut-off presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
asenapine. Where keeping to this makes it impossible to avoid
outcome titles with clumsy double-negatives (e.g. ’Not un-im-
proved’) we reported data where the left of the line indicates an
unfavourable outcome. We noted this in the relevant graphs.
Assessment of risk of bias in included studies
Again review authors AB, SD and MS, worked independently to
assess risk of bias by using criteria described in theCochrane Hand-
book for Systematic Reviews of Interventions to assess trial quality
(Higgins 2011b). This set of criteria is based on evidence of as-
sociations between overestimate of effect and high risk of bias of
the article such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
If the raters disagreed, we made the final rating by consensus, with
the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of
trials are provided, we attempted to contact the authors of the
studies in order to obtain further information. If there was non-
concurrence in quality assessment we would have reported this,
and if disputes had arisen regarding the category to which a trial
was to be allocated, again, we would have resolved by discussion.
We noted the level of risk of bias in both the text of the review
and in the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive than odds ratios (Boissel 1999),
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). The number needed to treat for an additional bene-
ficial outcome (NNTB)/number needed to treat for an additional
harmful outcome (NNTH) statistic with its confidence intervals
is intuitively attractive to clinicians but is problematic both in its
accurate calculation in meta-analyses and interpretation (Hutton
2009). For binary data presented in Summary of findings for the
main comparison, where possible, we calculated illustrative com-
parative risks.
2. Continuous data
For continuous outcomes we estimated mean difference (MD)
between groups. We prefered not to calculate effect size measures
(standardised mean difference (SMD)). However, if scales of very
considerable similarity had been used, we would have presumed
there was a small difference in measurement, and we would have
calculated effect size and transformed the effect back to the units
of one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error whereby P values are spuriously low, confidence
intervals unduly narrow and statistical significance overestimated
(Divine 1992). This causes type I errors (Bland 1997; Gulliford
1999).
In future versions of this review where clustering is not accounted
for in primary studies, wewill present data in the analysis, with a (*)
symbol to indicate the presence of a probable unit of analysis error.
We will seek to contact first authors of studies to obtain intra-class
correlation coefficients for their clustered data and to adjust for this
by using accepted methods (Gulliford 1999). Where clustering
has been incorporated into the analysis of primary studies, we will
present these data as if from a non-cluster randomised study, but
adjust for the clustering effect.
We have sought statistical advice and were advised that the binary
data presented in a report should be divided by a ’design effect’.
This is calculated using the mean number of participants per clus-
ter (m) and the intra-class correlation coefficient (ICC) [Design
effect = 1 + (m - 1) *ICC] (Donner 2002). If the ICC is not re-
ported it will be assumed to be 0.1 (Ukoumunne 1999).
If cluster studies are appropriately analysed taking into account
intra-class correlation coefficients and relevant data documented
in the report, synthesis with other studies will be possible using
the generic inverse variance technique.
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2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycholog-
ical) of the treatment in the first phase is carried over to the second
phase. As a consequence on entry to the second phase the partici-
pants can differ systematically from their initial state despite hav-
ing had a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
only used data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we would have presented the additional treatment arms in com-
parisons. If data are binary these would have simply been added
and combined within the two-by-two table. If data were contin-
uous we would have combined the data following the formula in
section 7.7.3.8 (Combining groups) of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). Where the
additional treatment arms were not relevant, we did not use these
data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up the data must lose credibility
(Xia 2009). We chose that, for any particular outcome, should
more than 50% of the data be unaccounted for, we would not
reproduce these data or use them within analyses. If, however,
more than 50% of those in one arm of a study were lost, but the
total loss is less than 50%, we addressed this within Summary of
findings for the main comparison by down-rating quality. Finally,
we also downgraded quality within Summary of findings for the
main comparison should loss be between 25% to 50% in total.
2. Binary
When attrition for a binary outcome is between 0% and 50%,
and where these data are not clearly described, we presented data
on a ’once-randomised-always-analyse’ basis (an intention-to-treat
analysis). We assumed those leaving the study early to have the
same rates of negative outcome as those who completed the study,
with the exception of the outcome of death and adverse effects.
For these outcomes we used the rate of those who stay in the study
- in that particular arm of the trial - for those who did not. We
intended, if possible, to undertake a sensitivity analysis testing how
prone the primary outcomes are to change when data only from
people who complete the study to that point are compared to the
intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
We used and entered data into analyses when attrition for a con-
tinuous outcome was between 0% and 50%, and data only from
people who completed the study to that point were reported.
3.2 Standard deviations
If standard deviations were not reported, we first tried to obtain
the missing values from the authors. If these were not available,
where there are missing measures of variance for continuous data,
but an exact standard error and confidence intervals are available
for group means, and either P value or ’t’ value are available for
differences in the mean, we calculated them according to the rules
described in theCochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a).When only the standard error (SE) is re-
ported, standard deviations (SDs) can be calculated by the formula
SD = SE * square root (n). Chapters 7.7.3 (Higgins 2011a) and
16.1.3 (Higgins 2011c) of the Cochrane Handbook for Systematic
Reviews of Interventions present detailed formulae for estimating
SDs from P values, t or F values, CIs, ranges or other statistics.
If these formulae do not apply, we calculated the SDs according
to a validated imputation method based on the SDs of the other
included studies (Furukawa 2006). Although some of these impu-
tation strategies can introduce error, the alternative would be to
exclude a given study’s outcome and thus to lose information. We
intended to examine the validity of the imputations in a sensitivity
analysis excluding imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
trials early or are lost to follow-up. Some trials present only the
results of study completers, others use the method of last observa-
tion carried forward (LOCF), while more recently methods such
as multiple imputation or mixed effects models for repeated mea-
surements (MMRM) have become more common. While the lat-
ter methods seem to be somewhat better than LOCF (Leon 2006),
we feel that the high percentage of participants leaving the stud-
ies early and differences in the reasons for leaving the studies be-
tween groups is often the core problem in randomised schizophre-
nia trials. We therefore did not exclude studies based on the sta-
tistical approach used. We prefered to use the more sophisticated
approaches. e.g. MMRM or multiple-imputation to LOCF, and
completer analysis was only presented if some kind of intention-
to-treat data were not available at all. Moreover, we addressed this
issue in the item ’incomplete outcome data’ in the risk of bias tool.
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Assessment of heterogeneity
1. Clinical heterogeneity
Initially we considered all included studies, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations that we had not
predicted would arise. We discussed any such situations or partic-
ipant groups when they arose.
2. Methodological heterogeneity
Initially we considered all included studies, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods that we had not
predicted would arise. We discussed any methodological outliers.
3. Statistical heterogeneity
3.1 Visual inspection
We inspected graphs visually to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 P value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I2 de-
pends firstly on magnitude and direction of effects and secondly
on the strength of evidence for heterogeneity (e.g. P value from
Chi2 test, or a confidence interval for I2). An I2 estimate greater
than or equal to around 50% accompanied by a statistically sig-
nificant Chi2 statistic, is interpreted as evidence of substantial lev-
els of heterogeneity (Cochrane Handbook for Systematic Reviews
of Interventions Section 9.5.2; Deeks 2011). If substantial levels
of heterogeneity were found in the primary outcome, we would
have explored reasons for heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are de-
scribed in section 10.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a).We tried to locate proto-
cols of included randomised trials. If the protocol was available, we
compared outcomes in the protocol and in the published report.
If the protocol was not available, we compared outcomes listed
in the methods section of the trial report with the results actually
reported.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
Again, these are described in Section 10 of theCochrane Handbook
for Systematic Reviews of Interventions (Sterne 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but have limited power to detect small-study effects. We did not
use funnel plots for outcomes where there are ten or fewer studies,
or where all studies are of similar sizes. In future versions of this
review, if funnel plots are possible, we will seek statistical advice
in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model as it puts added weight onto small studies,
which are often the most biased. Depending on the direction of
effect these studies can either inflate or deflate the effect size. We
chose to use a fixed-effect model for all analyses. The reader is,
however, able to choose to inspect the data using the random-
effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
To treat schizophrenia, asenapine is currently administered twice
a day in a 5 mg or 10 mg dose (FDA 2013). We intended to
conduct a subgroup analysis by asenapine dose (5 mg twice a day
versus placebo, 10 mg twice a day versus placebo) on any primary
outcome where there was significant heterogeneity (defined as I
2≤ 75; Higgins 2011a). We did not anticipate any subgroup anal-
yses concerning the form of administration of asenapine as it is
predominantly administered sublingually (FDA 2013).
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1.2 Clinical state, stage or problem
We proposed to undertake this review and provide an overview of
the effects of asenapine for people with schizophrenia in general.
In addition we intended, if possible, to report data on subgroups of
people in the same clinical state, stage and with similar problems.
2. Investigation of heterogeneity
We reported if inconsistency is high. Firstly we investigated
whether data had been entered correctly. Secondly, if data were
correct, we inspected the graph visually and successively removed
outlying studies to see if homogeneity was restored. For this review
we decided that should this occur with data contributing no more
than around 10% of the total weighting to the summary finding,
data were to be presented. If not, data would have been pooled
and issues discussed. We know of no supporting research for this
10% cut off, but are investigating use of prediction intervals as an
alternative to the current unsatisfactory state.
When unanticipated clinical or methodological heterogeneity is
obvious we will simply state hypotheses regarding them for future
reviews or versions of this review. We do not anticipate undertak-
ing analyses relating to unanticipated clinical or methodological
heterogeneity.
Sensitivity analysis
1. Implication of randomisation
We aimed, if possible, to include trials in a sensitivity analysis if
they were described in some way that implied randomisation. For
the primary outcomes we would have included these studies and if
there was no substantive difference when the implied randomised
studies were added to those with better description of randomisa-
tion, then all data from these studies would have been employed.
2. Assumptions for lost binary data
If assumptions had to be made regarding people lost to follow-
up (see Dealing with missing data) we would have compared the
findings of the primary outcomes when we used our assumptions
and whenwe used data only from people who completed the study
to that point. If there had been a substantial difference, we would
have reported results and discussed them, but continued to employ
our assumption.
For continuous data, if assumptions had to be made regarding
missing SDs (see Dealing with missing data), we would have com-
pared the findings of the primary outcomes when we used our
assumptions and when we used data only from people who com-
pleted the study to that point. A sensitivity analysis would have
been undertaken testing how prone results are to change when
completer-only data are compared to the imputed data using the
above assumption. If there is a substantial difference, we would
have reported results and discussed them, but continued to em-
ploy our assumption.
3. Risk of bias
We intended, if required, to analyse the effects of excluding trials
that are judged to be at high risk of bias across one or more of
the domains of randomisation (i.e. implied as randomised with no
further details available), allocation concealment, blinding, and
outcome reporting for themeta-analysis of the primary outcome. If
the exclusion of trials at high risk of bias did not substantially alter
the direction of effect or the precision of the effect estimates, then
data from these trials would have been included in the analysis.
4. Imputed values
We also, if required, intended to undertake a sensitivity analysis
to assess the effects of including data from trials where we used
imputed values for ICC in calculating the design effect in cluster
randomised trials.
5. Fixed-effect and random-effects
All data were synthesised using a fixed-effect model, however, we
also synthesised data for the primary outcome using a random-
effects model to evaluate whether this altered the significance of
the results
R E S U L T S
Description of studies
For in-depth descriptions of the studies please see Characteristics
of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
and Characteristics of ongoing studies.
Results of the search
Electronic searches identified 37 references with 4 additional
records identified through other sources. After duplicates were re-
moved, we screened 41 records and nine of these reports (seven
trials) did not meet the inclusion criteria (see Characteristics of
excluded studies) and had to be excluded. Additionally, two trials
(two reports) are awaiting classification, and one trial (one report)
is currently ongoing. Six trials (29 reports) are included (Figure
2).
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Figure 2. Study flow diagram.
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Included studies
1.1 Methods
The six included studies were explicitly described as ran-
domised (Chapel 2009; Kane 2011; NCT00151424; Kane 2010;
NCT00156117; Potkin 2007). Six weeks was a common trial
length (Kane 2010; Potkin 2007) and the duration varied from
the shortest trial lasting 16 days (Chapel 2009) and the longest
trial lasting 52 weeks (Kane 2011).
1.2 Setting
Three trials involved inpatients and outpatients (NCT00151424;
Kane 2010; Potkin 2007), The settings of the other studies were
not clearly specified.
1.3 Participants
All studies reported participants to have schizophrenia or schizoaf-
fective disorder using the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) or DSM-IV Text
Revision (DSM-IV-TR). Data from 1835 people are included in
the review.
1.4 Study size
The mean number of participants in each trial was 305, ranging
from 148 (Chapel 2009) to 458 (Kane 2010).
1.5 Interventions
1.5.1 Asenapine
The dose of asenapine ranged from 5mg to 20mg twice a day
(BID). Asenapine was administered sublingually.
1.5.2 Placebo
All trials compared asenapine with placebo which were indistin-
guishable from each other. Placebo was administered orally or sub-
lingually.
1.5.3 Other drug treatment arms
Five of the the trials included one more intervention arm along
with placebo and asenapine. These were quetiapine (Chapel
2009), risperidone (Potkin 2007), olanzapine (NCT00151424;
NCT00156117), and haloperidol (Kane 2010). The data for these
arms were not included in the review.
1.6 Outcomes
The outcomes reported by included studies were global state,men-
tal state, adverse effects and leaving the study early. None of the
included studies had any evidence of the clinical effects of ase-
napine/placebo on cognitive functioning, behaviour, functioning,
service utilisation, quality of life, or reported economic data.
The following scales were used and provided data for the analysis.
1.6.1 Global state
The Clinical Global Impression rating scales are used in various
mental disorders in order to quantify symptom severity, treatment
response and efficacy of treatment.
1.6.1.1 Clinical Global Impression (CGI) (Guy 1976)
A scale (seven points) is used in which clinicians are required to
rate the severity of the patient’s illness, with higher scores indi-
cating increased severity/reduced recovery. This measure requires
the clinician to use all available information including the history
of the patient, symptoms, social environment and impact on the
patient’s functioning.
1.6.1.2 Clinical Global Impression - Severity of Illness (CGI-
S)
A sub-scale of the CGI which requires clinicians to rate the current
severity of the patient’s illness compared to the clinician’s past
experience with patients. Mental illness is assessed on a seven-
point scale, scores ranging from one to seven, where a higher score
indicates a higher severity of illness.
1.6.1.3 Clinical Global Impression - Improvement (CGI-I)
A sub-scale of the CGI which requires the clinicians to rate the
extent to which the patient’s illness has deteriorated or improved
in comparison with a baseline state at the start of the intervention.
Again this uses a seven-point scale, scores ranging from one to
seven. A score of one indicates ’verymuch improved’, four indicates
’no change’, and seven indicates ’very much worse’.
1.6.2 Mental state
1.6.2.1 Positive and Negative Syndrome Scale (PANSS) (Kay 1987)
This is widely used in the form of a clinical interview with pa-
tients with schizophrenia to measure the severity of their symp-
toms. The interview items include three sub-scales, positive (seven
items), negative (seven items) and general psychopathology (16
items) whereby patients are rated from one to seven on the 30
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different symptoms. Therefore the lowest a patient can score on
the PANSS scale is 30. A higher score indicates a higher severity
of illness. The first two scales refer to the positive (hallucinations/
delusions) and negative (blunted effect/social and emotional with-
drawal) symptoms of schizophrenia. The general psychopathol-
ogy scale includes 16 items of which some include anxiety/guilt
feelings, tension, mannerisms, depression and motor retardation.
Often scores are given separately for the three different scales.
An alternative approach to scoring the PANSS is through the use
of clinician-ratedMarder factor sub-scales (Marder 1997). Follow-
ing factor analysis of the PANSS, five symptom dimensions were
identified. The sub-scales include positive symptoms (eight items;
score range of 8 - 56); negative symptoms (seven items; score range
of 7 - 49); disorganized thought (seven items; score range of 7 -
49); hostility/excitement (four items; score range of 4 - 28); and
anxiety/depression (four items; score range of 4 - 28).
1.6.2.2 Calgary Depression Scale for Schizophrenia (CDSS) (
Addington 1993)
This clinician-rated scale is used in order to assess depressive symp-
toms, usually in the form of a semi-structured interview, with
patients with schizophrenia. The items on the scale include de-
pressed mood, guilt (delusions/ pathological), hopelessness, low
self-esteem, observed depression, weight loss, disrupted sleep and
suicide. Scores range from 0 - 4, where a higher score indicates
higher severity of depression.
1.6.3 Adverse effects
1.6.3.1 Abnormal Involuntary Movement Scale (AIMS) (Munetz
1988)
A clinician-rated scale used to assess the severity of tardive dyskine-
sia, particularly in patients taking neuroleptic medications. There
are 12 Items, with scores ranging from zero to four, assessing fa-
cial movements, global severity, extremities, trunkmovements and
dental status. A higher score indicates higher severity.
1.6.3.2 Simpson - Angus Scale (SAS) (Simpson 1970)
A ten-item clinician-rated scale which assesses neuroleptic-in-
duced Parkinsonism (NIP) in schizophrenia. Signs assessed in-
clude head dropping, shoulder shaking, salivation, tremors and
elbow/wrist rigidity. A five-point scale with scores ranging from 0
- 40 is used to assess the severity, the higher the score the more
severe NIP.
1.6.3.3 Barnes Akathisia Scale (BAS) (Barnes 1989)
A clinician-rated rating scale in which drug-induced akathisia
severity is assessed. Items assess the frequency and objective pres-
ence of akathisia, the individual’s awareness and distress, and the
global severity. The objective and subjective ratings are scored from
zero to three where a higher score indicates higher severity of rest-
lessness, awareness of restlessness and distress related to restless-
ness. A six-point scale is used to assess global severity with scores
ranging from zero to five, a higher score specifies higher severity.
Excluded studies
Seven studies were excluded in this review. These are listed
in the Characteristics of excluded studies table. Three of the
studies were not randomised (Castle 2013; Leucht 2013; The
National Horizon Scanning Centre 2010). A further three did
not have a placebo control (Cazorla 2008; NCT00156065;
NCT01142596). Since we are only including studies with adult
participants we excluded NCT01190254 as this focused on ado-
lescents.
Studies awaiting classification
NCT00156091 and NCT01098110 meet our inclusion criteria
and would have been listed in the included studies if sufficient
information had been available. NCT01098110 has been recently
completed (April 2014). It is possible that their data analysis has
been completed since the time of writing and we will add this
information to future versions of this review if it is available.
Ongoing studies
One ongoing study has been identified (NCT01617187). This
randomised study was started in December 2012 and is estimated
to include 354 adults with schizophrenia. The study assesses the
effects of two doses of asenapine (2.5 mg and 5 mg BID) versus
placebo on global and mental state in a six-week trial. The esti-
mated date of completion for the study is September 2014. This
trial is being sponsored by Merck.
Risk of bias in included studies
Information for risk of bias across the included studies is illustrated
in Figure 3 and Figure 4.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The six studies do not explicitly describe the method used
for randomisation of participants, although they were “ran-
domised” (Chapel 2009; Kane 2011;NCT00151424; Kane 2010;
NCT00156117; Potkin 2007). Furthermore, no study provides
information on allocation concealment. As a result we had to rate
all studies as being of ’unclear’ risk of bias.
Blinding
All the included studies described blinding as “double-blind”,
however four of the six provide no further detail as to how
this was achieved (Chapel 2009; NCT00151424; Kane 2010;
NCT00156117). For this reason, we have rated them as ’unclear
risk’. Potkin 2007 and Kane 2011 we rated ’low risk’ as both stud-
ies provide some description of how the blinding was conducted.
A double dummy design was used where asenapine and placebo
tablets were identical in appearance and the patients and sites were
unaware of the identity of the tablets (Kane 2011, Potkin 2007).
The authors judge Kane 2011, to be ’high risk’ in the assessment of
an outcome. The rest of the studies do not describe how blinding
was done to assess the outcomes, therefore, they were deemed as
’unclear risk’.
Incomplete outcome data
All six included studies report loss to follow up and attrition
due to adverse effects, although this is not well documented in
some. Some attempt was made by five studies to address the attri-
tion by using the intention-to-treat (ITT) approach (Kane 2011;
NCT00151424; Kane 2010; NCT00156117; Potkin 2007; ).
However, inKane2011;NCT00151424;Kane2010; Potkin 2007
, the ITT approach was used in conjunction with last observation
carried forward (LOCF) for some of the outcomes. This can intro-
duce bias as it makes assumptions about the people who did not
complete the study. None of these studies attempted to validate
the assumptions made about these people and because of this, we
have rated them as ’high risk’. Chapel 2009 does not document
how the loss of participants was addressed for analysis and this,
too, has been rated as ’high risk’.
Selective reporting
Most of the studies had some degree of selective reporting or in-
sufficient reporting of data - with the exception of Kane 2010
which we thought was ’low risk’ as it provides usable data for
most outcomes. NCT00151424 and NCT00156117 are unpub-
lished trials with full data sets unavailable, however, we were able
to utilise some data for mental state, leaving the study early and
adverse effects. Themajority of studies provided tables, graphs and
visual representations of data. Some studies reported no means
or standard deviations for certain outcomes (Kane 2011; Potkin
2007). Chapel 2009 had unreported data of endpoint characteris-
tics for its primary outcome. We rated Chapel 2009; Kane 2011;
NCT00151424; NCT00156117; Potkin 2007 as ’high risk’ due
to missing, incomplete or unusable reporting of data.
Other potential sources of bias
All six studies were funded and supported by pharmaceutical com-
panies (Merck, Organon, Pfizer Inc, Schering-Plough). Nearly all
authors were affiliated with or employed by pharmaceutical com-
panies. This could lead to bias in the reporting. As a result, we
classed all the studies at ’high risk’.
Effects of interventions
See: Summary of findings for the main comparison
ASENAPINE versus PLACEBO for schizophrenia
COMPARISON 1: ASENAPINE versus PLACEBO
1.1 Global state: 1. No clinically important change (CGI-I) -
short-term (up to 12 weeks)
For this outcome we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.81, 95% CI 0.68 to 0.97, Analysis 1.1).
1.2 Global state: 2. Average change score (CGI-S, high =
poor)
1.2.1 Short-term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD - 0.35, 95% CI -0.55 to -0.15, Analysis 1.2).
1.2.2 Medium-term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -0.6, 95% CI -0.77 to -0.43, Analysis 1.2).
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1.3 Global state: 3. Relapse - medium-term (13 to 26 weeks)
For this outcome we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.26, 95% CI 0.18 to 0.40, Analysis 1.3).
1.4 Global state: 4. Use of any concomitant medication
1.4.1 Short-term
In this subgroup we only found one relevant trial (n = 340) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.84, 95% CI 0.74 to 0.97, Analysis 1.4).
1.4.2 Medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.87, 95% CI 0.71 to 1.07, Analysis 1.4).
1.5 Global state: 5. Use of specific concomitant medication
1.5.1 Acetaminophen - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.74, 95% CI 0.48 to 1.12, Analysis 1.5).
1.5.2 Antiparkinsonian medication - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 1.21,
95% CI 0.78 to 1.88, Analysis 1.5). This subgroup had moderate
levels of heterogeneity (Chi2 = 1.62; degrees of freedom (df ) = 1;
P = 0.203; I2 = 38%).
1.5.3 Benzatropine - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.05, 95% CI 0.43 to 2.57, Analysis 1.5).
1.5.4 Ibuprofen - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.61, 95% CI 0.30 to 1.22, Analysis 1.5).
1.5.5 Lorazepam - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 0.85,
95% CI 0.71 to 1.02, Analysis 1.5).
1.5.6 Lorazepam - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.45, 95% CI 0.16 to 1.27, Analysis 1.5).
1.5.7 Trihexyphenidyl - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.70, 95% CI 0.83 to 3.50, Analysis 1.5).
1.5.8 Trihexyphenidyl - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.66, 95% CI 0.19 to 2.30, Analysis 1.5).
1.5.9 Zolpidem - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 1.00,
95% CI 0.71 to 1.40, Analysis 1.5).
1.5.10 Zolpidem - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.33, 95% CI 0.07 to 1.61, Analysis 1.5).
1.6 Mental state: 1. No clinically important change (PANSS)
- short-term
For this outcome we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.72, 95% CI 0.59 to 0.86, Analysis 1.6).
1.7 Mental state: 2. Average change in total score (baseline-
to-endpoint) (PANSS, high = poor)
1.7.1 PANSS total score - short-term
In this subgroup we found two relevant trials (n = 627). There
was a clear difference between asenapine and placebo (MD -3.77,
95% CI -6.50 to -1.04, Analysis 1.7).
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1.7.2 PANSS total score - medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -10.80, 95% CI -13.57 to -8.03, Analysis 1.7).
1.8 Mental state: 3. Average change score (baseline-to-
endpoint) (various scales, high = poor)
1.8.1 CDSS total score - short-term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.86, 95% CI -1.62 to -0.10, Analysis 1.8).
1.8.2 CDSS total score - medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -0.70, 95% CI -1.25 to -0.15, Analysis 1.8).
1.8.3 PANSS Marder anxiety/depression factor score - short-
term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.55, 95% CI -1.26 to 0.16, Analysis 1.8).
1.8.4 PANSS Marder anxiety/depression factor score -
medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
((MD -1.40, 95% CI -1.95 to -0.85), Analysis 1.8).
1.8.5 PANSS Marder disorganized thought factor score -
short-term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -1.25, 95% CI -2.20 to -0.30, Analysis 1.8).
1.8.6 PANSS Marder disorganized thought factor score -
medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -2.40, 95% CI -2.95 to -1.85, Analysis 1.8).
1.8.7 PANSS Marder hostility/excitement factor score -
short-term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.50, 95% CI -1.21 to 0.21, Analysis 1.8).
1.8.8 PANSS Marder hostility/excitement factor score -
medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -2.00, 95% CI -2.55 to -1.45, Analysis 1.8).
1.8.9 PANSS Marder negative factor score - short-term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -1.10, 95% CI -2.29 to 0.09, Analysis 1.8).
1.8.10 PANSS Marder negative factor score - medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -1.70, 95% CI -2.53 to -0.87, Analysis 1.8).
1.8.11 PANSS Marder positive factor score - short-term
In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -2.40, 95% CI -3.83 to -0.97, Analysis 1.8).
1.8.12 PANSS Marder positive factor score - medium-term
In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -3.40, 95% CI -4.23 to -2.57, Analysis 1.8).
1.9 Adverse effects: 1. Incidence of serious adverse effects
1.9.1 Short-term
In this subgroup we found three relevant trials (n = 644). There
was no clear difference between asenapine and placebo (RR 1.12,
95% CI 0.63 to 2.00, Analysis 1.9).
1.9.2 Medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.29, 95% CI 0.14 to 0.63, Analysis 1.9).
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1.10 Adverse effects: 2. Incidence of any adverse effects
1.10.1 Any adverse effects - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 0.99,
95% CI 0.89 to 1.11, Analysis 1.10).
1.10.2 Any treatment-emergent adverse effects - medium-
term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.83, 95% CI 0.68 to 1.01, Analysis 1.10).
1.10.3 Any treatment-related adverse effects - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.18, 95% CI 0.91 to 1.52, Analysis 1.10).
1.10.4 Any treatment-related adverse effects - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.84, 95% CI 0.59 to 1.19, Analysis 1.10).
1.11 Adverse effects: 3. Incidence of adverse effects by
severity - short-term
1.11.1 Mild adverse effects
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.88, 95% CI 0.66 to 1.18, Analysis 1.11).
1.11.2 Moderate adverse effects
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.01, 95% CI 0.71 to 1.42, Analysis 1.11).
1.11.3 Severe adverse effects
In this subgroup we found three relevant trials (n = 644). There
was no clear difference between asenapine and placebo (RR 1.52,
95% CI 0.80 to 2.91, Analysis 1.11).
1.12 Adverse effects: 4. Specific adverse effects - 4.1.
Cardiovascular: incidence - short-term
1.12.1 QTc interval > 450 ms
In this subgroup we found two relevant trials (n = 232). There
was a clear difference between asenapine and placebo (RD - 0.01,
95% CI - 0.07 to 0.05, Analysis 1.12).
1.12.2 Sinus tachycardia
In this subgroup we only found one relevant trial (n = 121) (Potkin
2007). There was a clear difference between asenapine and placebo
(RD 0.01, 95% CI -0.11 to 0.12, Analysis 1.12).
1.13 Adverse effects: 4. Specific adverse effects - 4.2.
Gastrointestinal: incidence - short-term
1.13.1 Clinically significant gamma-glutamyl transpeptidase
levels
In this subgroup we only found one relevant trial (n = 183) (
NCT00151424). There was a clear difference between asenapine
and placebo (RR 3.62, 95% CI 1.24 to 10.57, Analysis 1.13).
1.13.2 Clinically significant alanine aminotransferase levels
In this subgroup we only found one relevant trial (n = 183) (
NCT00151424). There was a clear difference between asenapine
and placebo (RR 2.58, 95% CI 1.2 to 5.56, Analysis 1.13).
1.13.3 Constipation
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 1.05, 95% CI 0.36 to 3.08, Analysis 1.13).
1.13.4 Dyspepsia
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 0.84, 95% CI 0.24 to 2.98, Analysis 1.13).
1.13.5 Vomiting
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 1.31,
95% CI 0.61 to 2.84, Analysis 1.13).
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1.14 Adverse effects: 4. Specific adverse effects - 4.3.
Metabolic: incidence
1.14.1 Clinically significant fasting glucose levels - short-
term
In this subgroup we found three relevant trials (n = 641). There
was a clear difference between asenapine and placebo (RR 2.24,
95%CI 1.06 to 4.75, Analysis 1.14). This subgroup hadmoderate
levels of heterogeneity (Chi2 = 3.97; df = 2; P = 0.14; I2 = 50%).
1.14.2 Clinically significant fasting triglycerides levels -
short-term
In this subgroup we only found one relevant trial (n = 183) (
NCT00151424). There was a clear difference between asenapine
and placebo (RR 8.27, 95% CI 1.06 to 64.77, Analysis 1.14).
1.14.3 Clinically significant HbA1C levels - short-term
In this subgroup we only found one relevant trial (n = 183) (
NCT00151424). There was no clear difference between asenapine
and placebo (RR 7.23, 95% CI 0.38 to 138.03, Analysis 1.14).
1.14.4 Clinically significant hyperprolactinaemia - short-
term
In this subgroup we found two relevant trials (n = 458). There
was no clear difference between asenapine and placebo (RR 3.28,
95% CI 0.97 to 11.06, Analysis 1.14).
1.14.5 Clinically significant hyperprolactinaemia - medium-
term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.62, 95% CI 0.21 to 1.86, Analysis 1.14).
1.14.6 Clinically significant weight gain - short-term
In this subgroup we found three relevant trials (n = 623). There
was a clear difference between asenapine and placebo (RR 3.48,
95% CI 1.19 to 10.15, Analysis 1.14).
1.14.7 Clinically significant weight gain - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 6.93, 95% CI 0.86 to 55.77, Analysis 1.14).
1.14.8 Clinically significant weight loss - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.85 CI 0.14 to 5.02, Analysis 1.14).
1.14.9 Clinically significant weight loss - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.33, 95% CI 0.13 to 0.81, Analysis 1.14).
1.14.10 Weight gain - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 1.84, 95% CI 0.75 to 4.51, Analysis 1.14).
1.14.11 Weight loss - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.43 , 95%CI 0.18 to 1.03, Analysis 1.14).
1.15 Adverse effects: 4. Specific adverse effects - 4.4.
Metabolic: average change in prolactin levels (µg/L)
(baseline-to-endpoint) - short-term
For this outcome we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (MD 6.01, 95% CI - 3.35 to 15.37, Analysis 1.15).
1.16 Adverse effects: 4. Specific adverse effects - 4.5.
Metabolic: average change in weight (kg) (baseline-to-
endpoint)
1.16.1 Short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (MD 1.05, 95% CI -0.03 to 2.13, Analysis 1.16).
1.16.2 Medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (MD 1.20, 95% CI 0.46 to 1.94, Analysis 1.16).
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1.17 Adverse effects: 4. Specific adverse effects - 4.6. Other
specific adverse effects: incidence
1.17.1 Agitation - short-term
In this subgroup we found two relevant trials (n = 461). There was
a clear difference between asenapine and placebo (RR 0.50, 95%
CI 0.28 to 0.89, Analysis 1.17).
1.17.2 Agitation - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.36, 95% CI 0.12 to 1.11, Analysis 1.17).
1.17.3 Akathisia - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.84, 95% CI 0.61 to 5.53, Analysis 1.17).
1.17.4 Akathisia - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 1.32, 95% CI 0.3 to 5.82, Analysis 1.17).
1.17.5 Anxiety - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 1.01,
95% CI 0.52 to 1.96, Analysis 1.17).
1.17.6 Anxiety - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.75, 95% CI 0.41 to 1.40, Analysis 1.17).
1.17.7 Delusions - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.18, 95% CI 0.04 to 0.80, Analysis 1.17).
1.17.8 Dizziness - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 0.58, 95% CI 0.21 to 1.64, Analysis 1.17).
1.17.9 Fatigue - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 0.53, 95% CI 0.10 to 2.76, Analysis 1.17).
1.17.10 Hallucinations - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.08, 95% CI 0.01 to 0.58, Analysis 1.17).
1.17.11 Headache - short-term
In this subgroup we found two relevant trials (n = 461). There was
a clear difference between asenapine and placebo (RR 0.39, 95%
CI 0.22 to 0.71, Analysis 1.17).
1.17.12 Headache - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 2.97, 95% CI 0.61 to 14.53, Analysis 1.17).
1.17.13 Insomnia - short-term
In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 0.81, 95%
CI 0.50 to 1.31, Analysis 1.17). This subgroup had important
levels of heterogeneity (Chi2 = 2.79; df = 1; P = 0.09; I2 = 64%).
1.17.14 Insomnia - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.46, 95% CI 0.24 to 0.88, Analysis 1.17).
1.17.15 Nausea - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 1.44, 95% CI 0.62 to 3.34, Analysis 1.17).
1.17.16 Oral hypoesthesia - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.89, 95% CI 0.53 to 6.74, Analysis 1.17).
1.17.17 Pain - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 0.79, 95% CI 0.18 to 3.37, Analysis 1.17).
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1.17.18 Psychosis - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 1.58, 95% CI 0.47 to 5.31, Analysis 1.17).
1.17.19 Schizophrenia - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.29, 95% CI 0.14 to 0.59, Analysis 1.17).
1.17.20 Sedation - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.68, 95% CI 0.21 to 2.18, Analysis 1.17).
1.17.21 Somnolence - short-term
In this subgroup we found two relevant trials (n = 461). There
was no clear difference between asenapine and placebo (RR 1.88,
95% CI 0.86 to 4.08, Analysis 1.17).
1.17.22 Somnolence - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.49, 95% CI 0.05 to 5.41, Analysis 1.17).
1.17.23 Upper respiratory tract infection - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 1.4, 95% CI 0.33 to 6.00, Analysis 1.17).
1.17.24 Worsening psychotic symptoms - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 0.51, 95% CI 0.21 to 1.22, Analysis 1.17).
1.18 Adverse effects: 5. Extrapyramidal symptoms - 5.1.
Incidence
1.18.1 Any extrapyramidal symptoms - short-term
In this subgroup we found two relevant trials (n = 523). There was
a clear difference between asenapine and placebo (RR 1.74, 95%
CI 1.02 to 2.96, Analysis 1.18).
1.18.2 Any extrapyramidal symptoms - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.66, 95% CI 0.24 to 1.82, Analysis 1.18).
1.18.3 Dystonia - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 7.39, 95% CI 0.42 to 130.15, Analysis 1.18).
1.18.4 Hyperkinesia - short-term
In this subgroup we only found one relevant trial (n = 121) (Potkin
2007). No one experienced this outcome (Analysis 1.18).
1.18.5 Hypertonia - short-term
In this subgroup we only found one relevant trial (n = 121) (
Potkin 2007). There was no clear difference between asenapine
and placebo (RR 0.21, 95% CI 0.01 to 4.28, Analysis 1.18).
1.18.6 Muscle rigidity - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 8.53, 95% CI 0.49 to 148.12, Analysis 1.18).
1.18.7 Parkinsonism - short-term
In this subgroup we only found one relevant trial (n = 340) (
Kane 2010). There was no clear difference between asenapine and
placebo (RR 1.51, 95% CI 0.61 to 3.76, Analysis 1.18).
1.18.8 Parkinsonism - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.33, 95% CI 0.03 to 3.14, Analysis 1.18).
1.19 Adverse effects: 5. Extrapyramidal symptoms - 5.2.
Average change (baseline-to-endpoint) (various scales, high
= poor) - short-term
1.19.1 AIMS
In this subgroup we only found one relevant trial (n = 333) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.13, 95% CI -0.43 to 0.17, Analysis 1.19).
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1.19.2 BAS
In this subgroup we only found one relevant trial (n = 333) (Kane
2010). There was a clear difference between asenapine and placebo
(MD 0.11, 95% CI -0.05 to 0.27, Analysis 1.19).
1.19.3 SAS
In this subgroup we only found one relevant trial (n = 333) (
Kane 2010). There was no clear difference between asenapine and
placebo (MD 0.50, 95% CI -0.04 to 1.04, Analysis 1.19).
1.20 Adverse effects: 6. Incidence of death (for any reason) -
short-term
In this outcome we found two relevant trials (n = 523). There
was no clear difference between asenapine and placebo (RD -0.01,
95% CI -0.02 to 0.01, Analysis 1.20).
1.21 Leaving the study early
1.21.1 Any reason - short-term
In this subgroup we found five relevant trials (n = 1046). There
was no clear difference between asenapine and placebo (RR 0.91,
95%CI 0.80 to 1.04, Analysis 1.21). This subgroup hadmoderate
levels of heterogeneity (Chi2 = 7.02; df = 4; P = 0.13; I2 = 43%).
1.21.2 Any reason - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.49, 95% CI 0.38 to 0.62, Analysis 1.21).
1.21.3 Due to adverse effects - short-term
In this subgroup we found three relevant trials (n = 644). There
was no clear difference between asenapine and placebo (RR 0.89,
95% CI 0.54 to 1.47, Analysis 1.21).
1.21.4 Due to adverse effects - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.3, 95% CI 0.18 to 0.50, Analysis 1.21).
1.21.5 Due to lack of efficacy - short-term
In this subgroup we found two relevant trials (n = 457). There was
a clear difference between asenapine and placebo (RR 0.56, 95%
CI 0.38 to 0.81, Analysis 1.21).
1.21.6 Due to loss to follow up - medium-term
In this subgroup we only found one relevant trial (n=386) (Kane
2011). There was not a clear difference between asenapine and
placebo (RR 0.99 CI 0.2 to 4.84, Analysis 1.21).
1.21.7 Due to other reasons - short-term
In this subgroup we found two relevant trials (n = 457). There
was no clear difference between asenapine and placebo (RR 1.22,
95% CI 0.83 to 1.80, Analysis 1.21).
1.21.8 Due to other reasons - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 0.84, 95% CI 0.38 to 1.82, Analysis 1.21).
1.21.9 Due to relapse (not considered adverse effect) -
medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.25, 95% CI 0.13 to 0.49, Analysis 1.21).
1.21.10 Due to specific adverse effect: relapse - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.27 CI, 95% 0.16 to 0.47, Analysis 1.21).
1.21.11 Due to specific adverse effect: worsening of
schizophrenia - medium-term
In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.25, 95% CI 0.14 to 0.45, Analysis 1.21).
1.21.12 Due to withdrawal of consent - medium-term
In this subgroup we only found one relevant trial (n = 386) (
Kane 2011). There was no clear difference between asenapine and
placebo (RR 1.57, 95% CI 0.78 to 3.14, Analysis 1.21).
2. Subgroup analyses
No subgroup analyses were conducted.
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3. Sensitivity analyses
3.1 Implication of randomisation
No sensitivity analyses were possible, as all included studies for
the primary outcomes were explicitly described as having random
allocation procedures.
3.2 Assumptions for lost binary data
For the primary outcomes, no sensitivity analyses were possible, as
no included study reported binary data for completer-only popu-
lations.
3.3 Risk of bias
No sensitivity analyses were possible, as all included studies for the
primary outcomes were judged to be of high risk of bias in one or
more domains (randomisation, allocation concealment, blinding
and outcome reporting).
3.4 Imputed values
No sensitivity analyses were possible, as none of the included stud-
ies for the primary outcomes were cluster-randomised trials.
3.5 Fixed and random effects
For the primary outcomes, there was no difference in the results
when synthesising data using a fixed-effect model or a random-
effects model.
D I S C U S S I O N
Summary of main results
1. General
Six studies (29 reports) met the inclusion criteria for our review.
The summary below discusses the outcomes included in Summary
of findings for the main comparison. We have also considered the
impact of our findings upon clinical practice, patients’ decision-
making and policy-related directives.
2. Treatment effects
2.1 Clinically important change in global state
One short-term study (Kane 2010; n = 336) reported the out-
come of clinically important change in global state (considered
by this study as a CGI-I score of one or two). Compared with
placebo, asenapine was found to produce significantly greater clin-
ical change in global state. Although encouraging, this finding
must be considered with caution because of the ’low-quality’ and
limited quantity of evidence.
2.2 Clinically important change in mental state
The same short-term study (Kane 2010; n = 336) reported ’clin-
ically important change in mental state’ (considered as a > 30%
decrease in PANSS score). Compared with placebo, asenapine was
found to produce significantly greater clinical change in mental
state. Again, interpretation must be undertaken with caution be-
cause of the ’very low-quality’ and limited quantity of evidence.
2.3 Average change in negative symptoms
Again, the same short-term study (Kane 2010; n = 336) reported
on the outcome of average change innegative symptoms (measured
in this study using the PANSSMarder negative factor). Compared
with placebo, asenapine was found to produce significantly greater
reduction in negative symptoms. Again, caution must be taken
when interpreting this result due to the ’very low-quality’ and
limited quantity of evidence. This needs much more independent
verification.
2.4 Incidence of serious adverse effects
One medium-term study (Kane 2011; n=386) reported on the
outcome of incidence of serious adverse effects. Compared with
placebo, asenapine was found to produce significantly fewer in-
cidents of serious adverse effects. Again, caution must be taken
when interpreting this result due to the ’very low-quality’ and lim-
ited quantity of evidence. Additionally, Analysis 1.9 shows three
short-term studies also indicate no differences between asenapine
and placebo in the incidence of serious adverse effects. One would
expect an active drug to have adverse effects and some of these,
perhaps occasionally, to be serious. It could be that asenapine is
not associated with adverse effects that are serious. It could also
be that more trial-derived data are needed, as well as information
from other non-trial sources. It is also feasible that, in these trials,
selective reporting is more than a possibility. More independently-
derived data are needed.
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2.5 Clinically significant extrapyramidal symptoms
Although four studies reported on incidence of extrapyramidal
symptoms, and two reported on average change of extrapyrami-
dal symptoms from baseline-to-endpoint (using the AIMS, BAS
and SAS), no included trial reported on the incidence of clini-
cally significant extrapyramidal symptoms. Continuous measures
are important fine-grain ways of identifying symptoms or signs.
However, it adds little complexity to a study to ask raters or par-
ticipants about how important they really feel that problem to be.
Not to do this could impose a spurious importance to data, or
serve to help ignore issues that really bother people. This omission
is an indication that these studies were designed less for research
into the well being of people with schizophrenia and more for the
needs of companies.
2.6 Leaving the study early - for any reason
Five short-term studies (n = 1046) reported on the outcome of
’leaving the study early for any reason’. Analysis 1.21 indicates that
there is no difference between the discontinuation rates of asenap-
ine and placebo across the studies. While this may appear encour-
aging for the use of asenapine, discontinuation rates for asenapine
(42.5%) and placebo (48.7%) were both very high. Although our
analysis was characterised by moderate heterogeneity (I2 = 43%),
and differences in discontinuation became clear, favouring asenap-
ine, when the one outlying study Chapel 2009 (~2% weighting)
is removed to gain homogeneity, losses to follow up are still enor-
mous. While four studies attempt to report on specific reasons for
discontinuation, the similarly high rates of attrition are likely to
reflect poor study design and trial management. The most chaotic
of clinical situations would still be hard pressed to lose nearly half
the people with schizophrenia it was responsible for within a mat-
ter of six weeks. This indicates how odd and removed from real
world care these trials are.
2.7 Economic costs
We considered the direct and indirect economic costs of asenap-
ine treatment to be a highly important outcome that could influ-
ence its potential circulation in clinical practice for schizophrenia.
Suprisingly, no studies reported any data related to this outcome.
No study reported service use outcomes such as ’relapse’ or ’hos-
pitalisation’. These can often be used as a proxy in an economic
consideration of an intervention. With economics being such an
important part of consideration of care, it is notable that there are
no data at all for this new compound. It is hard not to conclude
that the companies producing these trials are hesitant about re-
porting any data which would lead to economic consideration.
3. Publication bias
Due to the limited number of studies, it was not sensible to con-
duct funnel plot analyses to investigate publication bias. However
we were unable to find full publications for two included stud-
ies (NCT00151424; NCT00156117) that were considered to be
’negative trials’ by their authors.
4. Subgroup analyses
We did not conduct subgroup analyses.
5. Sensitivity analyses
No sensitivity analyses were possible for the implication of ran-
domisation, assumptions for lost binary data, risk of bias, and im-
puted values. The results for the primary outcomes did not differ
when a random-effects model was applied instead of a fixed-effect
model.
Overall completeness and applicability of
evidence
1. Completeness
1.1 Outcomes
The outcomes that were reported by the studies that have been
included are global state, mental state, adverse effects and leaving
the study early.
For the primary outcomes, only Kane 2010 reported on clinically
important change in global state and clinically important change
in mental state. Therefore we consider that our included studies
insufficiently reported these primary outcomes.
Similarly, our included studies inconsistently reported on the ma-
jority of our secondary outcomes. Of our analyses, only the out-
come ’leaving the study early’ (Analysis 1.21) was reported on by
all six of our included studies.
None of the included studies had any evidence of the effects of ase-
napine versus placebo on cognitive functioning, behaviour, func-
tioning, service utilisation, quality of life, and economic costs. Of
the secondary outcomes, we believe the insufficient reporting of
’relapse’, and not reporting service outcomes such as ’admitted’,
particularly disappointing.
1.2 Duration
Of our included studies, five were short-term and one was
medium-term. We found no long-term studies.
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2. Applicability
2.1 Patients
Four of our included studies were global multicentred trials which
indicates the applicability of asenapine across different cultures.
However no included study reported a breakdown of participant
sample size and demographics of each centre fromwhich we could
draw stronger conclusions.
The majority of included studies predominately consisted of pa-
tients with schizophrenia (DSM-IV/DSM-IV-TR) which limits
the applicability of our findings to other schizophrenia-like dis-
orders (e.g. schizo-affective disorder, schizophreniform disorder,
delusional disorder). Furthermore, no included study clearly re-
ported upon the presence of psychiatric and physical co-morbidi-
ties. In addition, several included studies explicitly excluded co-
morbid conditions, which does not reflect everyday clinical prac-
tice. Therefore it is unclear whether our findings are applicable to
co-morbid populations.
2.2 Dosage
The dose of asenapine ranged from 5 mg to 20 mg twice a day
(BID). The dosage used by five of the included studies adhered
to the FDA recommendations (5 - 10 mg BID) (FDA 2013),
suggesting clinical applicability of the findings. Only one study
(Chapel 2009) exceeded the recommended dosage, using up to 20
mg BID.
2.3 Setting
Three included studies conducted the trial on an inpatient and
outpatient basis. However no study reported a breakdown of out-
come findings from each setting type. The settings of the other
included studies have not been clearly specified. In this respect,
the applicability of the findings is unclear.
2.4 Outcome term lengths
Five of our included studies were short-term and onewasmedium-
term. We found no long-term studies. Considering schizophre-
nia is a chronic illness and may require long-term medication
treatment, we consider the applicability of the short-term studies
to be limited, as far as the long-term prognosis of patients with
schizophrenia is concerned.
Quality of the evidence
We judged the bias of the included trials to be unclear/high (
Figure 3; Figure 4), and the quality of the current evidence to
be low or very low using GRADE (Summary of findings for the
main comparison) (Schünemann 2011). This is largely due to
poor trial design and management, methodological inadequacies
(randomisation and blinding), and high rates of discontinuation.
In addition, the included studies were characterised by missing or
unreported outcomes and poor clarity of follow-up. All trials were
sponsored by pharmaceutical companies and nearly all authors
were affiliated with, or employed by these companies.
Potential biases in the review process
We adhered to the protocol by independently inspecting citations
and full articles of potentially relevant studies. Furthermore we
independently extracted data onto simple forms, and discussed
any inconsistencies or disagreements that arose.
Agreements and disagreements with other
studies or reviews
To our knowledge, there are no other systematic reviews of ase-
napine versus placebo for schizophrenia. However, a small number
of pooled analyses and literature reviews (Bishara 2009; Citrome
2009; Leucht 2014; Stoner 2012; Szegedi 2012) were in line with
the findings from our review, as many of the studies they reported
were included in our analyses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Asenapine appears to be a promising atypical antipsychotic. There
is some, albeit preliminary, evidence of improvement in posi-
tive symptoms (delusions and hallucinations), negative symptoms
(which may include reduced affect, and reduced motivation), and
depressive symptoms. However due to the limited quality and
quantity of evidence, it remains difficult to recommend the use of
asenapine for schizophrenia. There are missing trials which may
add to the argument about which the study authors have not been
forthcoming.
2. For clinicians
The dosage used by five of the included studies adhered to the
FDA recommendations (5 - 10 mg BID) (FDA 2013), suggesting
clinical applicability of the findings. At present it is not possible to
be fully confident that asenapine is really suitable for the treatment
of people with schizophrenia, as ongoing trials are not complete or
data are missing from important studies that are completed. It is
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certainly impossible to make conclusive judgements on the long-
term effects of asenapine.
3. For managers/policy makers
The availability of asenapine is still relatively limited. We have no
real service data or economics to work with. For such a drug to
enter clinical practice, we suggest that such information should be
routinely produced as part of the output of evaluative studies.
Implications for research
1. General
Future studies investigating the clinical effects of asenapine need to
be well reported, and adhere to theCONSORT statement (Moher
2010). All outcomes from all trials must be easily accessible and
all data should be reported as numbers.
2. Specific
2.1 Reviews
This review will require updates in the future as, at present, there
are two studies awaiting classification, and one ongoing trial.
Five of our included studies involved an additional active treat-
ment arm. As detailed elsewhere, these data were excluded from
this review but could be used elsewhere (Table 1). However it is
important to identify the comparative effects of asenapine to other
antipsychotic agents. There are two Cochrane Systematic Reviews
currently underway comparing asenapine to typical antipsychotics
(Kumar 2012) and other atypical antipsychotics Preda 2010).
2.2 Trials
We identify a great need for larger-scale, longer-term and more
independent randomised controlled trials investigating the clini-
cal effects and safety of asenapine. Future long-term clinical tri-
als should clearly describe the random sequence generation and
concealment of allocation, as well as the thoroughly-tested dou-
ble-blinding procedures, whilst recruiting a sample size that pro-
vides high statistical power. Outcome measures that should addi-
tionally be investigated include relapse, functioning, service util-
isation, quality of life/satisfaction with care, and economic costs.
There are, however, studies underway or completed that may add
enough to this review to allow more firm conclusions to be drawn
(NCT00156091; NCT01098110; NCT01617187).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chapel 2009
Methods Allocation: random allocation.
Blindness: double-blind.
Duration: 16 days.
Funding: Organon - a part of Schering-Plough Corporation and Pfizer Inc
Country: six sites in the United States and one site in South Africa
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N: 148.
Age: 18 to 65 years (mean age 42.6 years).
Sex: 114 men and 34 women.
History: no details.
Interventions 1. Asenapine: 5 mg for 10 days followed by 10 mg for six days (BID) N = 38
2. Asenapine: 15 mg for 10 days followed by 20 mg for six days (BID) N = 38
3. Quetiapine: 375 mg for 16 days N = 37.
4. Placebo: for 16 days N=35.
Outcomes Usable:
Adverse effects (QTc prolongation-incidence, ECG, blood samples)
Leaving study early.
Unusable:
Adverse effects (QTc average change; and blood sample data not fully reported for
placebo; weight: only reported baseline data)
Notes Did not use data for quetiapine trial arm.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” - but no further descrip-
tion provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
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Chapel 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk From 148 participants, “Twenty- three pa-
tients withdrew before day 10 (eight owing
to adverse events), and 11 additional pa-
tients withdrew before day 16 (one owing
to an adverse event)”
No description of how the loss was ad-
dressed in the analysis
Selective reporting (reporting bias) High risk Endpoint population characteristics not
provided for QTc and weight
Other bias High risk “Financial support for this work was pro-
vided by Pfizer, Inc and Schering - Plough”
The authors were employed by Schering-
Plough or Pfizer, Inc at the time of trial
Kane 2010
Methods Allocation: random allocation; (1:1:1:1 distribution).
Blindness: double-blind.
Duration: six-week trial.
Funding: sponsored by Organon, Pfizer Inc.
Country: 43 sites in five countries (United States, Russia, India, Romania & Canada)
Participants Diagnosis: acute exacerbated schizophrenia (DSM-IV-TR).
91% diagnosis of paranoid schizophrenia.
N: 458.
Age: mean age range - 37 to 40 years.
Sex: 52% male.
History: mean age at onset of illness is 26 years (range 6 - 60 years)
50% exhibited current or past prominent negative symptoms.
54% had four or more previous episodes of acute schizophrenia requiring hospitalisation
29% had a history of one or more suicide attempts.
Majority of patients in each treatment group had a history of smoking within the past
six months
Interventions 1. Asenapine (5 mg, BID) N = 114.
2. Asenapine (10 mg, BID) N = 106.
3. Placebo N = 123.
4. Haloperidol (4 mg, BID) N = 115.
Outcomes Usable
Global State (CGI-S, CGI-I; concomitant drugs).
Mental State (change in PANSS total score; CDSS).
Adverse effects (AIMS, BAS, SAS; fasting glucose; prolactin; weight; deaths)
Leaving the study early.
Unusable
Mental state (ISST - no data reported).
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Kane 2010 (Continued)
Cognitive functioning (CNS vital signs - no data reported).
Adverse effects (weekly lab assessments; ECG - insufficient data reported)
Quality of life (QLS, Q-LSQ, PETIT - no data reported).
Readiness to discharge (no data reported).
Notes Did not use data for haloperidol trial arm.
For follow up: patients who complete six-week trial given option to continue for 52-
week trial (NCT00156065).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” - but no further descrip-
tion provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk “In all, 272 patients (61% of the ITT pop-
ulation) completed the study”
ITT population and LOCF and MMRM
method of analysis were used
Selective reporting (reporting bias) Low risk Most outcomes reported with mean and
standard deviations.
Other bias High risk Four of the authors were employed at
Merck or Pfizer, Inc at the time of trial. The
lead author was affiliated with Bristol -My-
ers Squibb, Otsuka Pharmaceuticals, Eli-
Lilly and Co, Janssen, Johnson & Johnson
PRD, MDS Pharma Services, Pfizer Inc,
Solvay Pharmaceutical Inc, Wyeth Phar-
maceuticals, Lundbeck,VandaPharmaceu-
ticals, Astra- Zeneca, Cephalon, Dainip-
pon Sumitomo, Glaxo Smith Kline, Intra-
cellular therapeutics, PGxHealth, Proteus,
Takeda and Schering- Plough
“....funded by Schering- Plough Corpora-
tion, now Merck & Co, Inc, (Whitehouse
Station, NJ, USA)”
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Kane 2011
Methods Allocation: random allocation.
Blindness: double-blind.
Duration: 52-week extended trial. Two phases: 26 weeks of open label treatment of
asenapine; 26 weeks of double-blind treatment (where they continued with asenapine
or were switched to placebo)
Funding: Merck
Country: United States, Russian Federation, Ukraine, India, Latvia and Croatia
Participants Diagnosis: schizophrenia (DSM-IV-TR)
N: 386
Age: range 18 to 78 years.
Sex: asenapine men (N = 105), asenapine women (N = 89), placebo men (N = 116),
placebo women (N = 76)
History: more than one prior acute schizophrenia episode during the preceding three
years and schizophrenia requiring continuous anti-psychotic treatment for more than
one year preceding screening
Interventions 1. Asenapine (10 mg BID) N = 194
2. Placebo N = 192
Outcomes Usable:
Global State (CGI-S; relapse; concomitant drugs).
Mental State (PANSS total score, PANSS Marder factor scores; mood - CDSS)
Adverse effects (weight, incidence of EPS - AIMS, BAS, SAS).
Leaving the study early.
Unusable:
Global State (time to relapse/impending relapse - nodata reported for asenapine reported)
Mental state (Modified ISST - no data reported).
Adverse effects (average change - no SDs reported for BAS, AIMS, SAS; ECG; hyper-
prolactinaemia)
Leaving the study early (time to early discontinuation - no average value reported for
each group)
Notes Subgroup analyses reported calculating incidence of concomitant medication used in
patients who experienced relapse/impending relapse; not to be included in meta-analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”.
“asenapine and placebo sublingual tablets
were identical in appearance”
“neither patients nor sites were aware of the
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Kane 2011 (Continued)
tablet identity”
Probably done.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Incidence of relapse: “Determination of re-
lapse/impending relapse was based on in-
vestigator judgement in 75%”
Possibility of biased judgement - high risk.
All other outcomes: no details provided -
unclear risk.
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 386 patients entered “only 207” com-
pleted the study.They used ITTpopulation
“Period end point is the last non-missing
post baseline assessment on or before last
double blind dose date plus 3d”
This suggests that LOCF method of anal-
ysis was used.
Selective reporting (reporting bias) High risk Data for time to relapse reported only for
placebo and not for asenapine
No standard deviations reported for spe-
cific adverse effects
Other bias High risk “This study was funded by Merck and
Pfizer Inc”.
All of the authors were either affiliated with
or employed by Merck or Schering-Plough
NCT00151424
Methods Allocation: random allocation.
Blindness: double-blind.
Duration: six-week trial
Funding: Organon.
Country: not provided.
Participants Diagnosis: schizophrenia.
N: treated sample: 275.
Age: over 18 years old.
Sex: men and women.
History: patients currently experiencing acute exacerbation of schizophrenia
Interventions 1. Asenapine (5 - 10 mg BID) N = 90.
2. Olanzapine (10 - 20 mg QD) N = 92.
3. Placebo N = 93.
Outcomes Usable:
Adverse effects (EPS, deaths, weight gain).
Leaving the study early.
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NCT00151424 (Continued)
Unusable:
Global state (CGI-S, CGI-I - no data reported).
Mental state (anxiety, depression, suicidal thinking - no data reported; PANSS - odds
ratios only, not able to input to generic inverse variance without faulting - statistical
advice being sought)
Cognitive functioning (no data reported).
Functioning (no data reported).
Adverse effects (EPS, laboratory parameters, vital signs, weight, ECGs - no data reported)
Quality of life (no data reported).
Readiness to discharge (no data reported).
Notes Three study authors contacted regarding further information about trial:
1. Prof. Potkin emailed twice, awaiting response.
2. Dr. Szegedi emailed once using Merck address, failed to deliver, unable to locate
current email address
3. Prof. Leucht provided contact details of colleagues considered better suited to provide
information, awaiting response from provided contacts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind - no further description.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk LOCF method was used for analysis.
Selective reporting (reporting bias) High risk No data reported for multiple out-
comes: global state (CGI-S, CGI-I), men-
tal state (PANSS, anxiety, depression, suici-
dal thinking), cognitive functioning, func-
tioning, specific adverse events, quality of
life, readiness to discharge
Other bias High risk Sponsored by Organon and Pfizer Inc.
Unpublished trial.
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NCT00156117
Methods Allocation: random allocation.
Blindness: double blind.
Duration: six-week trial.
Funding: Merck Sharp & Dohme Corp.
Country: not provided.
Participants Diagnosis: schizophrenia.
N: ITT sample: 386.
Age: over 18 years old.
Sex: men and women.
History: currently suffering from an acute exacerbation of schizophrenia
Interventions 1. Asenapine (5 mg BID) N = 102.
2. Asenapine (10 mg BID) N = 96.
3. Olanzapine (15 mg QD) N = 95.
4. Placebo N = 93.
Outcomes Usable:
Mental state (PANSS).
Leaving study early
Unusable (no data reported):
Global state (CGI-S, CGI-I).
Mental state (PANSS, anxiety, suicidal thinking).
Cognitive functioning.
Functioning.
Adverse effects (EPS, laboratory parameters, vital signs, weight, ECGs)
Quality of life.
Readiness to discharge.
Notes Four authors contacted regarding further information regarding trial:
1. Prof. Potkin emailed twice, awaiting response.
2. Dr. Szegedi emailed once using Merck address, failed to deliver, unable to locate
current email address
3. Prof. Leucht graciously provided contact details of colleagues considered better suited
to provide information, awaiting response from provided contacts
4. Prof. Castle graciously provided manuscript submitted for peer review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-Blind (subject, caregiver, investi-
gator, outcomes assessor)”
No further description.
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NCT00156117 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT sample was used for the study.
Selective reporting (reporting bias) High risk No data reported for multiple outcomes:
global state (CGI-S, CGI-I), mental state
(PANSS, anxiety, suicidal thinking), cogni-
tive functioning, functioning, specific ad-
verse events, quality of life, readiness to dis-
charge
Other bias High risk The study is funded by Schering-Plough.
Unpublished trial.
Potkin 2007
Methods Allocation: random allocation.
Blindness: double-blind; double-dummydesign: asenapine patients also received placebo
BID
Duration: six-week trial.
Funding: Organon Pharmaceuticals Inc.; Pfizer Inc.
Country: 21 sites in United States.
Participants Diagnosis: schizophrenia (DSM-IV); subtypes (including paranoid, disorganized, un-
differentiated)
N: randomised 180*.
Age: over 18 years old.
Sex: ~78% men, ~22% women.
History: duration of present episode:
Up to one month: 34 (58%) asenapine, 39 (63%) placebo.
One to six months: 21 (36%) asenapine, 16 (26%) placebo.
Over six months: 3 (5%) asenapine, 6 (10%) placebo.
Not specified or not obtained: 1 (2%) asenapine, 1 (2%) placebo
Interventions 1. Asenapine (5 mg BID - titrated) sublingual + oral placebo (BID) N = 59
2. Placebo (BID) oral + sublingual placebo (BID) N = 62.
3. Risperidone (3 mg BID) oral + oral placebo (BID) N = 59.*
Outcomes Usable:
Global State (use of concomitant drugs).
Adverse effects (ECG assessments, prolactin, glucose, incidence of QTc prolongation,
sinus tachycardia, weight gain)
Leaving the study early.
Unusable:
Global state (CGI-S - loss of data > 50%; adherence to trial - no data reported)
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Potkin 2007 (Continued)
Mental state (PANSS - loss of data > 50%).
Cognitive functioning (neurocognitive battery - no data reported)
Adverse effects (blood pressure, heart rate, temperature, respiratory rate, cholesterol,
triglycerides, QTc, weight gain - data without SDs, SEs or P values; EPS - data without
SDs, SEs, or P values for BAS, SAS, AIMS)
Notes *Did not use risperidone trial arm.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - but no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“In this double-dummy design, asenapine-
treated patients also received oral placebo
BID...and patients in the placebo-control
group received oral and sublingual placebo
BID”
Probably done.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk “For the intention-to-treat population...
the primary outcome measure (change
from baseline in PANSS total score with
asenapine vs. placebo at end point or last
observation carried forward [LOCF]) was
analysed using least-squares means based
on two-way analysis of variance, with treat-
ment and center as factors. For secondary
outcome measures, similar comparisons
were made for asenapine versus placebo...”
Discontinuation rate > 50%; ITT popula-
tion and LOCF method of analysis were
used
Selective reporting (reporting bias) High risk No SDs reported for changes in PANSS
total, positive, negative and general psy-
chopathology scores; changes in CGI-S
scores; actual weight gain, changes in total
cholesterol, fasting triglycerides and QTc
Only adverse events in
>
=10% patients of
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Potkin 2007 (Continued)
any treatment group (of treated popula-
tion) were reported
Other bias High risk “Financial support for this trial was pro-
vided by Organon Pharmaceuticals USA
Inc”
Funded and supported by Organon Phar-
maceuticals USA/International Inc. and
Pfizer Inc
General abbreviations
BID - bis in die (twice daily)
CNS - Central nervous system
DSM-IV - Diagnostic and Statistical Manual - Fourth Edition
DSM-IV-TR - Diagnostic and Statistical Manual - Fourth Edition, Text Revision
ECG - Electrocardiogram
EPS - Extrapyramidal symptoms
ITT - Intention-to-treat
LOCF - Last observation carried forward
MMRM - Mixed model of repeated measures
QD - quaque die (everyday)
SD - Standard deviation
SE - Standard error
Scales
AIMS - Abnormal involuntary movement scale
BAS - Barnes akathisia scale
CDSS - The Calgary depression scale for schizophrenia
CGI-I - Clinical global impression - Improvement scale
CGI-S - Clinical global impression - Severity scale
ISST - InterSePT scale for suicidal thinking
PANSS - Positive and negative syndrome scale
PETIT - Personal evaluation of transitions in treatment
QLS - The quality of life scale for schizophrenia
Q-LES-Q - Quality of life enjoyment and satisfaction questionnaire
Q-LSQ - Quality of life in depression scale
RDQ - Readiness to discharge questionnaire
SAS - Simpson-Angus Scale
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Castle 2013 Allocation: not randomised, pooled analysis of three asenapine vs. placebo RCTs
(Potkin 2007; Kane 2010; NCT00156117).
Cazorla 2008 Allocation: random allocation
Participants: adults (over 18 years old) diagnosed with schizophrenia
Intervention: asenapine versus olanzapine; no placebo control
NCT00156065 Allocation: random allocation
Participants: adults (over 18 years old) diagnosed with schizophrenia
Intervention: asenapine 5 - 10 mg BID versus asenapine 5 - 10 mg plus placebo BID
versus haloperidol 2 - 8 mg BID; no placebo control
NCT01142596 Allocation: random allocation
Participants: adults (over 20 years old) diagnosed with schizophrenia
Intervention: asenapine 5 mg BID versus asenapine 10 mg BID; no placebo control
NCT01190254 Allocation: random allocation
Participants: adolescents (12 to 18 years old) diagnosed with schizophrenia, not
adults
The National Horizon Scanning Centre 2010 Allocation: not randomised; summary of information fromclinical trials of asenapine
BID - Bis in die (twice daily)
RCT - Randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00156091
Methods Allocation: random allocation
Blindness: double-blind
Duration: 52-week trial
Funding: Merck Sharp & Dohme Corp.
Country: not provided
Participants Diagnosis: schizophrenia (DSM-IV)
N: 260
Age: over 18 years old
Sex: men and women
History: no details
Interventions 1. Asenapine (5 or 10 mg BID)
2. Olanzapine (20 mg QD)
3. Placebo
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NCT00156091 (Continued)
Outcomes Global State
Mental State (mean change in PANSS total score; CDSS).
Cognitive functioning
Functioning
Adverse effects (vital signs, EPS, ISST, weight, ECG, physical exams and lab tests)
Quality of life (QLS, Q-LES-Q, PETIT).
Notes NCT00156091
NCT01098110
Methods Allocation: random allocation
Blindness: double-blind
Duration: six week trial
Funding: Schering - Plough
Country: not provided
Participants Diagnosis: schizophrenia (DSM-IV)
N: 528
Age: 20-64 years
Sex: men and women
History: no details
Interventions 1. Asenapine (5 or 10 mg BID)
2. Olanzapine (20 mg QD)
3. Placebo
Outcomes Mental state (change in PANSS total score)
Notes NCT01098110
BID - bis in die (twice daily).
CDSS - The Calgary depression scale for schizophrenia.
DSM-IV - Diagnostic and Statistical Manual - fourth edition.
ECG - Electrocardiogram.
EPS - Extrapyramidal symptoms.
ISST - InterSePT scale for suicidal thinking.
PANSS - Positive and negative syndrome scale.
PETIT- Personal evaluation of transitions in treatment.
QD - quaque die (everyday).
Q-LES-Q - Quality of life enjoyment and satisfaction questionnaire.
QLS - The quality of life scale for schizophrenia.
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Characteristics of ongoing studies [ordered by study ID]
NCT01617187
Trial name or title A study of the efficacy and safety of asenapine in participants with an acute exacerbation of schizophrenia.
NCT01617187
Methods Allocation: random allocation
Blindness: double-blind
Duration: six-week trial
Funding: Merck
Country: Croatia & Ukraine
Participants Diagnosis: schizophrenia (DSM-IV)
N: estimated 354
Age: over 18 years old
Sex: men and women
History: no details
Interventions 1. Asenapine (2.5 mg BID)
2. Asenapine (5 mg BID)
3. Placebo
4. Olanzapine (15 mg QD)
Outcomes Mental State (Change in PANSS total score; number of participants with greater than or equal to 30%
reduction)
Global State (Change in CGI-S score).
Starting date Study start date: December 2012.
Contact information Toll Free Number: 1888-577-8839
Notes
BID - bis in die (twice daily).
CGI-S - Clinical global impression - Severity scale.
DSM-IV - Diagnostic and Statistical Manual - fourth edition.
PANSS - Positive and Negative Syndrome Scale.
QD - quaque die (everyday).
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D A T A A N D A N A L Y S E S
Comparison 1. ASENAPINE versus PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. No clinically
important change (CGI-I) -
short-term (up to 12 weeks)
1 336 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.68, 0.97]
2 Global state: 2. Average change
score (CGI-S, high=poor)
2 718 Mean Difference (IV, Fixed, 95% CI) -0.50 [-0.62, -0.37]
2.1 short-term (up to 12
weeks)
1 336 Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.55, -0.15]
2.2 medium-term (13 to 26
weeks)
1 382 Mean Difference (IV, Fixed, 95% CI) -0.60 [-0.77, -0.43]
3 Global state: 3. Relapse -
medium-term (13 to 26 weeks)
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.18, 0.40]
4 Global state: 4. Use of any
concomitant medication
2 726 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.76, 0.96]
4.1 short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.74, 0.97]
4.2 medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.71, 1.07]
5 Global state: 5. Use of specific
concomitant medication
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 acetaminophen - short-
term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.12]
5.2 antiparkinsonian
medication - short-term
2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.78, 1.88]
5.3 benzatropine - short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.43, 2.57]
5.4 ibuprofen - short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.30, 1.22]
5.5 lorazepam - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.71, 1.02]
5.6 lorazepam - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.16, 1.27]
5.7 trihexyphenidyl - short-
term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.83, 3.50]
5.8 trihexyphenidyl -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.19, 2.30]
5.9 zolpidem - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.71, 1.40]
5.10 zolpidem - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.61]
6 Mental state: 1. No clinically
important change (PANSS) -
short-term
1 336 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.86]
7 Mental state: 2. Average change
in total score (baseline-to-
endpoint) (PANSS, high=poor)
3 1009 Mean Difference (IV, Fixed, 95% CI) -7.24 [-9.18, -5.29]
7.1 PANSS total score - short-
term
2 627 Mean Difference (IV, Fixed, 95% CI) -3.77 [-6.50, -1.04]
7.2 PANSS total score -
medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -10.80 [-13.57, -8.
03]
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8 Mental state: 3. Average change
score (baseline-to-endpoint)
(various scales, high=poor)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 CDSS total score - short-
term
1 336 Mean Difference (IV, Fixed, 95% CI) -0.86 [-1.62, -0.10]
8.2 CDSS total score -
medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.25, -0.15]
8.3 PANSS Marder anxiety/
depression factor score - short-
term
1 336 Mean Difference (IV, Fixed, 95% CI) -0.55 [-1.26, 0.16]
8.4 PANSS Marder anxiety/
depression factor score -
medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -1.4 [-1.95, -0.85]
8.5 PANSS Marder
disorganized thought factor
score - short-term
1 336 Mean Difference (IV, Fixed, 95% CI) -1.25 [-2.20, -0.30]
8.6 PANSS Marder
disorganized thought factor
score - medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -2.4 [-2.95, -1.85]
8.7 PANSS Marder hostility/
excitement factor score - short-
term
1 336 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.21, 0.21]
8.8 PANSS Marder hostility/
excitement factor score -
medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -2.0 [-2.55, -1.45]
8.9 PANSS Marder negative
factor score - short-term
1 336 Mean Difference (IV, Fixed, 95% CI) -1.10 [-2.29, 0.09]
8.10 PANSS Marder negative
factor score - medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -1.7 [-2.53, -0.87]
8.11 PANSS Marder positive
factor score - short-term
1 336 Mean Difference (IV, Fixed, 95% CI) -2.40 [-3.83, -0.97]
8.12 PANSS Marder positive
factor score - medium-term
1 382 Mean Difference (IV, Fixed, 95% CI) -3.4 [-4.23, -2.57]
9 Adverse effects: 1. Incidence of
serious adverse effects
4 1030 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.42, 1.00]
9.1 short-term 3 644 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.63, 2.00]
9.2 medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.14, 0.63]
10 Adverse effects: 2. Incidence of
any adverse effects
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 any adverse effects -
short-term
2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.89, 1.11]
10.2 any treatment-emergent
adverse effects - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
10.3 any treatment-related
adverse effects - short-term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.91, 1.52]
10.4 any treatment-related
adverse effects - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.59, 1.19]
11 Adverse effects: 3. Incidence
of adverse effects by severity -
short-term
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 mild adverse effects 1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.66, 1.18]
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11.2 moderate adverse effects 1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.71, 1.42]
11.3 severe adverse effects 3 644 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.80, 2.91]
12 Adverse effects: 4. Specific
adverse effects - 4.1.
Cardiovascular: incidence -
short-term
2 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
12.1 QTc interval >450ms 2 232 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.07, 0.05]
12.2 sinus tachycardia 1 121 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.11, 0.12]
13 Adverse effects: 4. Specific
adverse effects - 4.2.
Gastrointestinal: incidence -
short-term
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 clinically significant
gamma-glutamyl
transpeptidase levels
1 183 Risk Ratio (M-H, Fixed, 95% CI) 3.62 [1.24, 10.57]
13.2 clinically significant
alanine aminotransferase levels
1 183 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [1.20, 5.56]
13.3 constipation 1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.36, 3.08]
13.4 dyspepsia 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.24, 2.98]
13.5 vomiting 2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.61, 2.84]
14 Adverse effects: 4. Specific
adverse effects - 4.3. Metabolic:
incidence
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 clinically significant
fasting glucose levels - short-
term
3 641 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.06, 4.75]
14.2 clinically significant
fasting triglycerides levels -
short-term
1 183 Risk Ratio (M-H, Fixed, 95% CI) 8.27 [1.06, 64.77]
14.3 clinically significant
HbA1C levels - short-term
1 183 Risk Ratio (M-H, Fixed, 95% CI) 7.23 [0.38, 138.03]
14.4 clinically significant
hyperprolactinaemia - short-
term
2 458 Risk Ratio (M-H, Fixed, 95% CI) 3.28 [0.97, 11.06]
14.5 clinically significant
hyperprolactinaemia -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.21, 1.86]
14.6 clinically significant
weight gain - short-term
3 623 Risk Ratio (M-H, Fixed, 95% CI) 3.48 [1.19, 10.15]
14.7 clinically significant
weight gain - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 6.93 [0.86, 55.77]
14.8 clinically significant
weight loss - short-term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.14, 5.02]
14.9 clinically significant
weight loss - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.13, 0.81]
14.10 weight gain - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.75, 4.51]
14.11 weight loss - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.18, 1.03]
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15 Adverse effects: 4. Specific
adverse effects - 4.4. Metabolic:
average change in prolactin
levels (µg/L) (baseline-to-
endpoint) - short-term
1 340 Mean Difference (IV, Fixed, 95% CI) 6.01 [-3.35, 15.37]
16 Adverse effects: 4. Specific
adverse effects - 4.5. Metabolic:
average change in weight (kg)
(baseline-to-endpoint)
2 726 Mean Difference (IV, Fixed, 95% CI) 1.15 [0.54, 1.76]
16.1 short-term 1 340 Mean Difference (IV, Fixed, 95% CI) 1.05 [-0.03, 2.13]
16.2 medium-term 1 386 Mean Difference (IV, Fixed, 95% CI) 1.2 [0.46, 1.94]
17 Adverse effects: 4. Specific
adverse effects - 4.6. Other
specific adverse effects:
incidence
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 agitation - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.28, 0.89]
17.2 agitation - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.12, 1.11]
17.3 akathisia - short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.61, 5.53]
17.4 akathisia - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.30, 5.82]
17.5 anxiety - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.52, 1.96]
17.6 anxiety - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.41, 1.40]
17.7 delusions - medium-term 1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.80]
17.8 dizziness - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.21, 1.64]
17.9 fatigue - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.10, 2.76]
17.10 hallucinations -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.58]
17.11 headache - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.22, 0.71]
17.12 headache - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [0.61, 14.53]
17.13 insomnia - short-term 2 461 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.50, 1.31]
17.14 insomnia - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.24, 0.88]
17.15 nausea - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.62, 3.34]
17.16 oral hypoesthesia -
short-term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [0.53, 6.74]
17.17 pain - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.18, 3.37]
17.18 psychosis - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.47, 5.31]
17.19 schizophrenia -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.14, 0.59]
17.20 sedation - short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.21, 2.18]
17.21 somnolence - short-
term
2 461 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.86, 4.08]
17.22 somnolence - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.05, 5.41]
17.23 upper respiratory tract
infection - short-term
1 121 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.33, 6.00]
17.24 worsening psychotic
symptoms - short-term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.21, 1.22]
18 Adverse effects: 5.
Extrapyramidal symptoms - 5.
1 Incidence
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
54Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
18.1 any extrapyramidal
symptoms - short-term
2 523 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.02, 2.96]
18.2 any extrapyramidal
symptoms - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.24, 1.82]
18.3 dystonia - short-term 1 340 Risk Ratio (M-H, Fixed, 95% CI) 7.39 [0.42, 130.15]
18.4 hyperkinesia - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.5 hypertonia - short-term 1 121 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.28]
18.6 muscle rigidity - short-
term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 8.53 [0.49, 148.12]
18.7 Parkinsonism - short-
term
1 340 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.61, 3.76]
18.8 Parkinsonism - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.14]
19 Adverse effects: 5.
Extrapyramidal symptoms - 5.
2. Average change (baseline-to-
endpoint) (various scales, high=
poor) - short-term
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 AIMS 1 333 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.43, 0.17]
19.2 BAS 1 333 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.05, 0.27]
19.3 SAS 1 333 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.04, 1.04]
20 Adverse effects: 6. Incidence of
death (for any reason) - short-
term
2 523 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.02, 0.01]
21 Leaving the study early 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 any reason - short-term 5 1046 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.80, 1.04]
21.2 any reason - medium-
term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.38, 0.62]
21.3 due to adverse effects -
short-term
3 644 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.54, 1.47]
21.4 due to adverse effects -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.18, 0.50]
21.5 due to lack of efficacy -
short-term
2 457 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.38, 0.81]
21.6 due to loss to follow up -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.20, 4.84]
21.7 due to other reasons -
short-term
2 457 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.83, 1.80]
21.8 due to other reasons -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.38, 1.82]
21.9 due to relapse (not
considered adverse effect) -
medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.13, 0.49]
21.10 due to specific adverse
effect: relapse - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.16, 0.47]
21.11 due to specific
adverse effect: worsening of
schizophrenia - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.14, 0.45]
21.12 due to withdrawal of
consent - medium-term
1 386 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.78, 3.14]
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A D D I T I O N A L T A B L E S
Table 1. Studies in this review which are relevant to others
Study Comparison Relevant existing Cochrane review
adults adolescents
with schizophrenia
Chapel 2009; NCT00156065;
NCT01142596;
Kane 2010; NCT00156117;
NCT01617187
Asenapine dose None underway
NCT00156065; Kane 2010 Asenapine versus haloperidol Kumar 2012
Cazorla 2008; NCT00151424;
NCT00156117;
NCT00156091;
NCT01098110;
NCT01617187
Asenapine versus olanzapine Preda 2010
Chapel 2009 Asenapine versus quetiapine
Potkin 2007 Asenapine versus risperidone
NCT01190254 Asenapine dose None underway
Asenapine versus placebo None underway
Kane 2010 Haloperidol versus placebo Adams 2013
NCT00151424;
NCT00156117;
NCT00156091;
NCT01098110;
NCT01617187
Olanzapine versus placebo Duggan 2005
Chapel 2009 Quetiapine versus placebo Lankappa 2012
Potkin 2007 Risperidone versus placebo Rattehalli 2010
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
After seeking advice, we used the Mantel-Haenszel method to compute Risk Differences (RD) rather than Risk Ratio (RR) for binary
outcomes in which at least one study had zero events in both asenapine and placebo trial arms. This included 1.12.1 QTc interval >
450ms and 1.21 Adverse effects: 6. Incidence of death.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [adverse effects; ∗therapeutic use]; Heterocyclic Compounds, 4 or More Rings [adverse effects; ∗therapeutic use];
Psychotic Disorders [drug therapy]; Randomized Controlled Trials as Topic; Schizophrenia [∗drug therapy]; Treatment Outcome
MeSH check words
Adult; Humans
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